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1 Summary  
Frequent Loss of Heterozygocity (LOH) in specific chromosomal regions of 
tumors indicates the residence of at least one tumor suppressor gene (TSG) in the 
corresponding chromosomal region. Chromosome 8p22 is described as LOH hotspot 
in several epithelial tumors. However, the related genes of this chromosomal band 
are still very poorly described. The aim of this study was the identification and 
characterization of potential tumor suppressor genes on chromosome 8p22 in 
ovarian cancer. 
Two out of 22 genes of 8p22 – hVps37A and TUSC3 – turned out to be 
promising tumor suppressor candidates and were characterized in more detail. It 
could be shown that hVps37 expression is significantly reduced in primary ovarian 
tumors relative to normal ovarian epithelias. Furthermore, survival rates of the 
patients were directly correlated with the hVps37A expression of the corresponding 
tumors. In-vitro characterization of hVps37A in two ovarian cancer cell lines resulted 
in an explanatory model of the clinical observations. As part of the ESCRT-I complex 
hVps37A is involved in the degradation process of activated receptor tyrosine 
kinases (RTKs) including the well described oncogenes EGFR and HER2. 
Consequently, hVps37A knockdown led to a hyperactivation of the MAPK (Mitogen 
Activated Protein Kinase) pathway secondary to accumulating amounts of the 
activated EGFR (pEGFR) in the cytoplasm. Furthermore, the hVps37-silenced cell 
lines developed a resistance against the growth inhibitory effect of Cetuximab.  
In contrast to hVps37A, 29.7% of the tumors analyzed were methylated at the 
TUSC3 promoter, acompanied with reduced mRNA expression and unfavourable 
survival rate of the patients. Therefore, promoter methylation turned out to be an 
independent prognostic factor for ovarian cancer. In-vitro, it could be shown that 
TUSCS3 resides in the endoplasmatic reticulum and is involved in the N-glycosilation 
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process of integrin-ß1 and potentially further proteins. Moreover, reconstitution of 
TUSC3 in ovarian cancer cell lines decreased cellular proliferation.  
Overall two promising molecular biomarkers were identified, potentially 
assisting in the development of more accurate prognostic procedures and therapies 
for ovarian cancer and beyond.  
 
1.1 Zusammenfassung 
Häufiges Auftreten eines Allelverlusts (Loss of Heterozygosity) in einer 
bestimmten Chromosomenregion bei Tumoren deutet darauf hin, dass in dieser 
Region mit hoher Wahrscheinlichkeit ein oder mehrere Tumorsuppressorgene (TSG) 
liegen. Loss of Heterozygosity (LOH) des Chromosoms 8p22 wurde in verschiedenen 
epithelialen Tumoren bereits häufig beschrieben, jedoch sind die meisten darauf 
liegenden Gene noch schlecht charakterisiert. Ziel dieser Arbeit war die 
Identifizierung und Charakterisierung potentieller TSG Kandidaten in dieser Region 
am Modellsystem des Ovarialkarzinoms. 
Aus 22 bekannten Genen dieser Region erschienen zwei Kandidaten – 
hVps37A und TUSC3 – besonders vielversprechend und wurden genauer 
charakterisiert. Es konnte gezeigt werden, dass die hVps37A Expression in primären 
Ovarialtumoren im Vergleich zu gesunden Epithelien des Ovars signifikant erniedrigt 
ist. Außerdem korreliert die Überlebenswahrscheinlichkeit von Ovarialkarzinom 
Patientinnen direkt mit der hVps37A mRNA Expression der korrespondierenden 
Tumore. Eine molekularbiologische Charakterisierung von hVps37A anhand von zwei 
Ovarialkarzinom Zelllinien lieferte ein Erklärungsmodell für die klinischen 
Beobachtungen. Als Teil des ESCRT-I Komplexes ist hVps37A am Abbau von 
Rezeptor Tyrosinkinasen (RTKs) inklusive der Onkogene EGFR und HER2 beteiligt.  
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Daher führte ein hVps37A Knock-down in unseren Zellmodellen zur Akkumulation 
des aktivierten EGR (pEGFR) im Cytoplamsa, was wiederum die Hyperaktivierung 
des MAPK (Mitogen Activated Protein Kinase) Pathways zur Folge hatte. Außerdem 
erwarben die Zelllinien als Folge des hVps37A Knock-downs eine Resistenz 
gegenüber der proliferationsinhibierenden Wirkung von Cetuximab.  
Im Unterschied zu hVps37A waren 29.7% der untersuchten Tumore am 
TUSC3 Promotor methyliert, was mit verringerter mRNA Expression und einer 
signifikant schlechteren Überlebenswahrscheinlichkeit für die Patientinnen 
einherging. Somit erwies sich für TUSC3 die Promotormethylierung als unabhängiger 
prognostischer Faktor. Rekonstituierung von TUSC3 in Ovarialkarzinomzelllinien 
führte zu einer verringerten Proliferation. Außerdem konnte gezeigt werden, dass es 
im endoplasmatischen Retikulum lokalisiert und an der N-Glykosylierung von 
Integrin-ß1 und potentiell weiteren Proteinen beteiligt ist. 
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2 Introduction 
 
2.1 Ovarian Cancer 
In industrialized countries, ovarian cancer is the leading cause of death from 
gynaecological malignancies (Jemal et al., 2008). It can be divided into three main 
groups: Epithelial, stromal and germ cell tumors, whereof epithelial tumors are most 
common and account for more than 85% of all ovarian cancer cases. Epithelial 
ovarian tumors may be serous or mucinous and include cystadenocarcinoma, 
endometrioid carcinoma, clear cell carcinoma, undifferentiated carcinoma, 
carcinosarcoma and mixed mesodermal tumor. Individual tumors are classified 
according to the FIGO staging system.  
Hereditary causes like mutations of BRCA1, BRCA2, MLH1, MSH2 or GSTM1 
 are believed to account for 10-15% of ovarian cancer development(Aarnio et al., 
1999; Watson et al., 2001). However, the bigger part of ovarian tumors occur 
spontaneously secondary to somatic mutations of oncogenes and/or tumor 
suppressor genes, leading to abnormal signalling of specific pathways like the PI3K-
AKT, the MAPK or the  mismatch-repair (MMR) pathway (Ricciardelli and Oehler, 
2009). 
 
2.2 Oncogenes and Tumor Suppressor Genes 
Oncogenes and tumor suppressor genes TSGs regulate different cellular 
mechansims like proliferation, apoptosis or DNA-repair. While oncogenes promote 
cellular growth, migration, invasion and survival, tumor suppressor genes 
counterbalance these effects. The rise of malignant tumors including ovarian cancer 
is a multistep event with subsequent dominant activating mutations of proto-
oncogenes or recessive inactivation  of TSGs (by mutations, deletions or promoter 
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methylation), leading to physiological alterations of the cellular phenotype, which is 
proceeding via a selection process according to the Darwinian evolution. 
Tumor suppressor genes are frequently located on LOH (loss of heterozygosity) 
regions, which are generated by chromosomal loss, somatic recombination or gene 
conversion (Figure 1). If one allele of a tumor suppressor gene is (e.g. hereditary) 
inactivated, the remaining wildtype allele can be lost by LOH, leading to 
transcriptional repression and cancer phenotype. Since repression of TSGs confers 
an advantage for tumors, a cancer cell-specific selection process accumulates LOH 
regions bearing at least one tumor supressor genes in cancer. Consequently, LOH 
regions can be used to indentify novel tumor suppressor genes. 
A 
 
B Fig.1 LOH can develop by A) 
somatic recombination, rarely 
occurring during the G2 of M-Phase 
(Nature Reviews Genetics 6, 568-
580), B), gene conversion which is 
associated with double strand 
breaks and mismatch repair or C) 
chromososomal loss, also caused 
by double strand breaks (Genetics, 
Vol. 153, 665-679, October 1999) 
 
 
 
 
 
2.3 Anti- Ovarian Cancer Interventions and Tumor Markers 
Because of few early stage symptoms and a lack of standard screenings, 
more than 70% of the ovarian carcinomas have already metastasized beyond the 
ovary when diagnosed. Consequently, the mortality rate of ovarian cancer patients is 
relatively high and chemotherapy is mostly needed in addition to debulking surgery.  
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Due to its high efficiency and low toxicity, the platinum-taxane combined therapy has 
been established as first-line treatment and also upon tumor recurrence(Sandercock 
et al., 2002). However, in the course of tumor relapse and subsequent treatments, 
response rates decrease as a result of gained resistance against first-line 
therapeutics. Platinum-resistent patients are alternatively treated with agents like 
gemcitabine, topotecan or etoposide, although there is no standard agreed following-
therapy available and response rates are still relatively poor for women who 
developed resistance against conventional chemotherapy (Agarwal and Kaye, 2003). 
Currently, a number of promising cytotoxic drugs are under investigation and some of 
them already proofed to be effective against recurrent ovarian tumors resistant 
against standard therapies (Krasner et al., 2007). Furthermore, several monoclonal 
antibodies or small-molecule inhibitors targeting essential components of ovarian 
cancer-related pathways emerge now as potential future therapeutics (Yap et al., 
2009). Angiogenesis inhibitors targeting the VEGFA (vascuolar endothelial growth 
factor A) (Bevacicumab) or the VEGFR (vascuolar endothelial growth factor receptor) 
tyrosine kinase domain (pazopanib, sunitinib, sorafenib and cediranib) are currently 
tested in clinical trials and are giving promising results (Yap et al., 2009). EGFR and 
HER2 are well described oncogenes of the Erbb-family, frequently overexpressed in 
ovarian cancer and thus serving as potential targets for anti-tumor interventions. 
However, single agent administration of anti-EGFR (Cetuximab, Matuzumab, 
Geftinib, Erlotinib) as well as anti-HER2 (Trastuzumab, Pertuzumab) compounds 
resulted in modest activity against relapsed cases of ovarian cancer (Yap et al., 
2009). 
Variations in therapy response are frequently resulting from different genetic profiles 
and molecular heterogeneity of the tumors. Conventional clinical markers including 
staging according to FIGO, histotype and grading, response to a first line 
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chemotherapy and amount of residual tumor after primary debulking surgery are 
insufficient to account for resistance against ovarian cancer therapies. However, 
apart from Cancer Antigen 125 (CA-125) (4) there are no specific diagnostic and 
prognostic molecular markers available in clinical practice (5).  
Therefore it is crucial to identify novel prognostic markers facilitating classification of 
ovarian carcinomas into pathogenetic subtypes and guiding between available 
therapy options. Aberrations of oncogenes (e.g. EGFR, HER2) or tumor suppressor 
genes (TSGs) (e.g. p53) of the apoptotic or pro-survival are believed to essentially 
account for resistance against chemotherapy. In addition to deletions and mutations, 
TSGs can be downregulated by epigenetic mechanisms like promoter methylation, 
which holds a particular promise as new molecular marker. They can give insight into 
the biology of a tumor and in contrast to gene or protein expression analysis, they 
can be easily detected by PCR-based methods in tumor material as well as in body 
fluids (6-8).  
 
2.4 Project Aims and Results Summary 
In this project, two candidate tumor suppressor genes (hVps37A and TUSC3) which 
may serve as potential biomoarkers for ovarian cancer, were identified and 
characterized. They reside on chromosome 8p22, a region of relatively high LOH 
amounts in epithelial tumors and were selected from 22 known genes on 
chromosome 8p22, since expression analysis resulted in a significantly reduced 
expression of hVps37A and TUSC3 in primary ovarian tumors compared to normal 
epithelial cells. Functional analysis of both candidates yielded promising 
observations: hVps37A is a member of the ESCRT-I complex, which is crucial for the 
endosomal sorting process of receptor tyrosine kinases (RTKs) including the 
oncogenes EGFR and HER2. Knock-down of hVps37A in two ovarian cancer cell 
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lines was associated with hyperactivation of the MAPK-pathway secondary to the 
accumulation of activated EGFR (pEGFR) in the cytoplasmic compartment of the 
cells. Although hVps37A knock-down did not essentially affect cellular proliferation, it 
reversed the growth-inhibitory effect of the monoclonal EGFR-antagonizing antibody 
Cetuximab. Furthermore, low hVps37A mRNA expression resulted in unfavourable 
survival rates of ovarian cancer patients and the prognostic significance of both 
EGFR and HER2 is strictly dependent on hVps37A protein expression levels.  
The TUSC3 promotor was found to be frequently methylated in primary ovarian 
tumors, leading to reduced expression levels and having a strong influence on overall 
as well as progression-free survival, independently of other prognostic factors. In 
vitro, TUSC3 was observed to reside within the endoplasmatic reticulum modifying N-
glycosylation patterns of integrin ß1 (and potentially other proteins), resulting in 
decreased adhesion to collagen I. Moreover, TUSC3 reconstitution in ovarian cancer 
cell lines was associated with a cell morphology change as well as decreased 
proliferation and elevated migration. 
Overall, hVps37A and TUSC3 bear a high potential as novel tumor suppressor genes 
in ovarian cancer and hVps37A might be established as first molecular prognostic 
markers for targeted therapies using monoclonal antibodies against RTKs like the 
EGFR. 
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3.1.1 Abstract 
hVps37A resides on chromosome 8p22, a common LOH region in several 
cancers. As a potential member of the human ESCRT-I complex, HVPS37A may be 
crucial for the degradation process of ubiquitinated receptor tyrosine kinases (RTKs). 
We found HVPS37A expression significantly reduced as well as being the 
determining influence of the prognostic value of EGFR in ovarian cancer (OC). 
HVPS37A down-regulation in OC cells led to cytoplasmic pEGFR retention and 
hyperactivation of the MAPK pathway. Furthermore, based on sustained AKT-
pathway activation, HVPS37A-silenced cells became irresponsive towards anti-
EGFR antibody inhibition.  Overall, we describe a novel prognostic biomarker for OC, 
clarify its influence on EGFR degradation and, by that, suggest a basis for a further 
refinement of anti-EGFR intervention in cancer. 
3.1.2 Introduction 
The ERBB receptor tyrosine kinase (RTK) family comprises four members 
(ERBB1-4), of which ERBB2 (HER2) and ERBB3 are non-autonomously functional. 
The epidermal growth factor receptor (EGFR, ERBB1) is a 170 kDa transmembrane 
RTK that plays an essential role in governing multiple cellular processes, including 
cell proliferation, survival, and migration (Hynes et al., 2001; Hynes and Lane, 2005). 
Activation by EGF or EGF-like ligands leads to autophosphorylation of cytoplasmic 
residues and receptor dimerization (Bogdan and Klambt, 2001). The phospho-
tyrosine residue itself serves as a docking platform for several adaptor molecules, 
triggering the activation of different pathways like the RAS-RAF-MEK-ERK pathway, 
the PI3K-AKT pathway, and the PLC-gamma-PKC pathway (Scaltriti and Baselga, 
2006).  Hyperactivation of EGFR-dependent signal transduction often accompanies 
tumor development, and cancer patients with unbalanced EGFR activity generally  
present a more aggressive disease leading to unfavorable clinical outcome (Holbro et 
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al., 2003). It is widely believed that hyperactivation of EGFR-mediated signal 
transduction can be triggered by the following means:  (1) increased ligand 
expression,  (2) elevated EGFR protein expression, (3) specific mutations, rendering 
EGFR constitutively active, (4) defective down-regulation of EGFR, and (5) cross-talk 
with heterologous receptor systems (Zandi et al., 2007). 
Down-regulation of EGFR and a number of other transmembrane proteins is 
realized via the endosomal sorting process, which depends on receptor endocytosis 
as well as subsequent vesicular shuttling towards one of three distinct cytoplasmic 
compartments (Maxfield and McGraw, 2004) as follows: (I) An internalized receptor 
can be directed back to the cell surface; (II) receptors enter the trans-Golgi network 
(TNG), or (III) receptors are transported into the intraluminal vesicles (ILVs) forming 
multivesicular bodies (MVBs), which are subsequently degraded upon fusion with the 
lysosome (Katzmann et al., 2002; Raiborg et al., 2003). 
 
MVBs arise upon subsequent binding of four mayor protein complexes 
(ESCRT-0-III; endosomal complex required for transport) to the limiting membran of 
sorting endosomes. Protein subunits (termed as vacuolar protein sorting; Vps) of 
these complexes are well conserved over the eucaryotic kingdom and some of them 
are described as potential tumor suppressor genes. It is believed that they contribute 
to cancer prevention by sorting tumor-relevant receptors into the ILVs of MVBs, 
leading to cessation of the receptor signal (Gruenberg and Stenmark, 2004). This 
mechanism is reported to regulate cell polarity and proliferation (Giebel and Wodarz, 
2006). As an example, mutant vps25 (a member of the ESCRT-II complex) exhibit 
Notch and Dpp receptor activation, leading to elevated proliferation rates of mutant 
and adjacent cells, accompanied by loss of epithelial organization (Thompson et al., 
2005). Tsg101 (Vps23), the most accuratly described ESCRT-I subunit in mammals, 
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is suggested to be essential for endosomal trafficking of several activated surface 
receptors and Tsg101 mutantions may contribute to a tumorgenic phenotype (Babst 
et al., 2000). Vps37A (vacuolar protein sorting 37 homolog A) was initially described 
in yeast as further subunit of ESCRT-I (Katzmann et al., 2001). The human 
homologue of Vps37A (hVps37A), is located on the short arm of chromosome 8 and 
in this very region, 8p22, high LOH frequencies are described for years in several 
human cancers including ovarian cancer. Only recently, the tumor suppressor gene 
DLC1 has been identified on 8p22 by a systematic genomic approach and several 
further candidates predicted (Pils et al., 2005b; Xue et al., 2008). The expression of 
hVps37A was found to be reduced or undetectable in hepatocellular carcinoma 
(HCC) (Xu et al., 2003) by a positional cloning approach as well and independently 
from its homology to Vps37A and consequently the name HVPS37A (hepatocellular 
carcinoma related protein) suggested. First functional data showed that  
overexpression in the HCC cell line SMMC-7721 significantly inhibited cell growth in 
vitro, whereas siRNA mediated knock-down of HVPS37A in the HCC cell line BEL-
7404 resulted in significantly increased cellular proliferation (Xu et al., 2003). In more 
detailed analysis following the functional studies of Vps37A in yeast it was shown 
that, via its mod(r) domain hVps37A interacts with Tsg101 and hVps28, as well as 
with its upstream regulator Hrs (hVps27). In the HeLa cell line, depletion of hVps37A 
diminishes EGFR degradation (Bache et al., 2004a).  With all this information 
available, hVps37A is still very poorly characterized. Since hVps37A was reported to 
be involved in the EGFR degradation process and regulating cellular proliferation, we 
suspected that it might have clinical relevance in OC, which is strongly dependent on 
EGFR signaling.  In fact, low hVps37A expression in primary tumor samples, as well 
as in recurrent intraperitoneal metastasis, was associated with an unfavorable course 
of disease for OC patients. Moreover, the well known prognostic influence of EGFR 
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expression was strictly dependent on the level of hVps37A protein expression. We 
further aimed to investigate the molecular basis behind this observation in two 
selected OC cell lines. hVps37A knock-down in OC cells caused accumulation of the 
activated EGFR (pEGFR) in the cytoplasmic compartment, initiating hyperactivation 
of the MAPK (mitogen activated protein kinase) pathway. Next we asked, whether 
hVps37A can interfere with therapeutic interventions targeting the EGFR, and 
detected that hVps37A-silenced OC cells gain resistance against EGFR inhibition by 
a monoclonal antibody, but not by small molecules. Taken together, our results 
identify and characterize a novel prognostic biomarker in OC and, potentially beyond, 
lead to a more comprehensive understanding of EGFR degradation in general.  This 
also implies there is a chance for a more sophisticated use of targeted therapies in 
RTK-driven cancer in the future.  
3.1.3 Results 
3.1.3.1 hVps37A Expression is Significantly Reduced in Primary Ovarian 
Tumors and has an Impact on Overall Survival 
hVps37A mRNA expression was quantified in 88 primary ovarian tumors, 38 
recurrent intraperitoneal metastases tumors, and 21 normal ovarian tissues 
(controls). The clinicopathologic characteristics of the patient cohort are outlined in 
Table 1.  
Consistent with our previous results (Pils et al., 2005b), we found that 
hVps37A expression is significantly reduced in primary tumors (p=0.002) compared 
to the controls. Interestingly, hVps37A expression levels in recurrent tumors and 
normal ovarian tissues were comparable (p=0.397), indicating a selection pressure 
against hVps37A expression, particularly in the early stage carcinogenesis 
(Figure 2A) Survival curves for hVps37A expression dichotomized at the median are 
visualized as Kaplan-Meier plot (Figure 2B). The influence of hVps37A on overall 
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survival reached statistical significance in a univariate model (p=0.017), as well as in 
a multivariate model (p=0.027) adjusted for grading, staging and morphologic 
subtype of the tumors (Table 2). 
 
 
 
 
 
 
 
 
 
 
 
Fig 2. hVps37A Inversely Correlates with Tumor Grade and has an Impact on Survival 
(A) hVps37A expression (y-axis) of 88 primary tumors, 38 recurrent tumors, and 21 
normal controls was quantified by qRT-PCR and depicted in boxplots. Sample 
distributions were calculated by the Mann-Whitney U test (p-value is indicated). 
(B) Survival analysis was realized by Cox proportional hazards regression 
models (Chi-Square=5.185; p=0.023), depicted in plots of the corresponding 
Kaplan-Meier estimations. Grey/black lines indicate samples high/low hVps37A 
amounts 
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Table 1. cDNA  Tissue Microarray: 
Characteristics of Patients N (percent) N (percent) 
Type   
Normal ovaries 21 (14.3)  
Primary tumors 88 (59.9) 125 (86.8) 
Recurrent tumors 38 (25.9)  
Borderline tumors  19 (13.2) 
Grade (1 missing) (8 missing) 
1 2 (1.6) 20 (17.1) 
2 50 (40.0) 26 (22.2) 
3 73 (58.4) 61 (60.7) 
FIGO (23 missing)  
I 21 (20.4) 31 (24.8) 
II 11 (10.7) 14 (11.2) 
III 51 (49.5) 72 (57.6) 
IV 20 (19.4) 8 (6.4) 
Histo (32 missing)  
Serous 78 (83%) 70 (56) 
Non-serous 16 (17%) 55 (44) 
 
 
 
Table 2. Univariate and Multiple Cox Proportional Hazards Analysis 
 univariate multivariate 
 Rel. Risk 95% CI P Rel. Risk 95% CI P 
hVps37A 4.72 1.33-16.67 0.017* 5.78 1.22-27.80 0.027* 
Grade 1.16 0.46-2.91 0.751 2.56 0.76-8.62 0.131 
FIGO 9.64 2.93-31.70 <0.001* 16.45 4.11-57.77 <0.001* 
Histology 1.29 0.48-3.52 0.614 2.65 0.63-11.24 0.186 
CI, confidence interval 
3.1.3.2 hVps37A Expression is Down-Regulated in Human Ovarian Cancer 
Since no commercial hVps37A-specific antibody was available, we raised a 
polyclonal antibody against a selected peptide of hVps37A in rabbit, followed by 
affinity purification.  First, we stained the MDAH-2774 cell line, in which we knocked 
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hVps37A down by a shRNA approach.  The cells were grown, fixed on chamber 
slides and stained as described in Experimental Procedures. Upon hVps37A-specific 
immunocytochemistry (ICC), the control cells exhibited potent hVps37A-specific 
staining, whereas the hVps37A deficient cell line remained almost negative. These 
results confirm the hVps37A knock-down in the MDAH-2774 cell line and qualify the 
antibody for ICC.  Further, we immunostained three control ovarian tissues and five 
ovarian carcinomas with the hVps37A antibody.  In accordance with our previous 
results on mRNA level, we found that the hVps37A protein amount was reduced in 
ovarian tumors compared to normal epithelia (Figure 3). 
 
Fig. 3. hVps37A Antibody is Applicable for IHC 
MDAH-2274 cells were transfected with (A) a nonsense construct (MDAH Co), or 
(B) a shRNA sequence directed against hVps37A (MDAH hVps37A-) as negative 
control. Cells were fixed on chamber slides and stained by our self-established 
polyclonal antibody specific against hVps37A. Staining specificity of the antibody 
was further confirmed in normal ovarian epithelial cells (C) and epithelial-derived 
ovarian tumors (D). 
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3.1.3.3 Prognostic Value of EGFR and HER2 is Tightly Related to hVps37A 
Status 
 Since our data of hVps37A suggests a crucial role of hVps37A for endosomal 
RTK-degradation, it might potentially influence the impact of EGFR/HER2 expression 
on the survival of OC patients. Thus, we undertook a tissue microarray (TMA) 
analysis to test this hypothesis. Median follow-up for patients with malignant tumors 
was 40.0 months (range 0.4–168.7 months), and 38 patients (30.4%) had already 
died. The TMAs were immunostained for EGFR and HER2 expression, as these 
receptors represent (1) well-established markers for ovarian carcinogenesis and 
progression and are (2) subject to hVps37A-dependent receptor degradation. HER2 
receptor was stained with the DAKO HercepTest and interpreted following the 
standard procedures for breast cancer diagnosis. The same interpretation procedure 
was used for the EGFR. Not unexpectedly, high protein expression of the oncogenes 
EGFR (p=0.015), as well as HER2 (p=0.003), was associated with unfavorable 
overall survival rates, thus confirming our previous results and those of others (Pils et 
al., 2007a). Further, the TMAs were immunostained with an hVps37A-specific 
antibody. The tissue staining was graded according to staining intensity and the 
patient cohort was divided at the median into two subgroups according to hVps37A 
expression. Interestingly, in the tumors with low hVps37A expression, we observed a 
strong impact of EGFR (p=0.008) as well as HER2 (p<0.001) expression levels on 
overall survival. In case of regular hVps37A expression, the well known prognostic 
influence of EGFR and HER2 was almost completely lost (Figure 4). This observation 
suggested a significant influence of the dynamics of receptor decay mechanisms on 
the clinical relevance of pathologic receptor expression. Thus, EGFR or HER2 
overexpression led to more aggressive cancers, almost exclusively under conditions 
of low hVps37A expression. 
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Fig. 4. hVps37A Expression Modulated Prognostic Potential of EGFR and 
HER2 
Tissue microarrays composed of 125 primary ovarian tumor samples and 19 
borderline tumors spotted in triplicates and corresponding normal tissue were 
stained for hVps37A, EGFR (A-C) and HER2 (D-F). (A) A complete set of samples 
stained against EGFR; (B) hVps37A-low expressing samples stained against 
EGFR; (C) hVps37A-high expressing samples stained against EGFR; (D) A 
complete set of samples stained against HER2; (E) hVps37A-low expressing 
samples stained against HER2; and (F) hVps37A-high expressing samples stained 
against HER2. Staining intensities were classified as described in Material and 
Methods. Statistical analysis was realized by Cox proportional hazards regression 
models for survival analysis, depicted in plots of the corresponding Kaplan-Meier 
estimations. 
 
3.1.3.4 Activated EGFR and HER2 Accumulate in hVps37A-Negative Cell Lines 
Since hVps37A was suggested to be involved in the endosomal sorting 
process of RTKs (Bache et al., 2004a), we supposed that its observed impact on 
patients’ survival may be related to altered receptor levels secondary to hVps37A 
depletion. EGFR and HER2, two members of the ERBB RTK-family, are established 
oncogenes crucial for ovarian carcinogenesis. Therefore, we chose them as a cellular 
model system for further studying the biological processes governed by hVps37A in 
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ovarian tumors. SK-OV-3 and MDAH-2774 ovarian cancer cell lines bear equal 
amounts of EGFR while having high (SK-OV-3) or low (MDAH-2774) HER2 
expression, respectively (Figurer 5A). Thus, they can be regarded as useful tools to 
investigate the role of hVps37A in the context of EGFR and HER2 receptor biology. 
To study the cellular effects of decreased hVps37A expression, hVps37A mRNA was 
stably knocked down in aforementioned cell lines via a shRNA approach. In order to 
calculate the silencing efficiencies, hVps37A mRNA and protein levels were 
determined in each stable clone and quantified relative to the hVps37A expression of 
the nonsense-controls (Figure 5B-E). For both cell lines, we obtained clones with 60-
70% reduction of hVps37A mRNA/protein, leading to elevated levels of activated 
EGFR. Activated HER2 could only be detected in the SK-OV-3 cell line, where it was 
found to be increased at similar rates as pEGFR (Figure 5B, D). In contrast, total 
receptor levels remained unaffected.  
 
 
 
 
 
 
 
 
 
A 
Results 20
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. hVps37A Knock-Down is Associated with pEGF/pHER2 Accumulation 
(A) EGFR and HER2 expression was quantified by western blotting in the MDAH-
2774 and SK-OV-3 ovarian cancer cell lines.  
(B, D) These cell lines were treated with shRNA constructs specific against 
hVps37A. Knock-down efficiency and receptor levels (EGFR, pEGFR, HER2 and 
pHER2) were determined by western blotting.  
(C, E) Successful knock-down of hVps37A was confirmed on mRNA level by qRT-
PCR. 
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These results were reproduced in five different MDAH clones with reduced 
hVps37A abundance, as well as in the SK-OV-3 cell line induced or not for silencing 
of hVps37A. In each stable hVps37A-silenced clone, we observed elevated pEGFR 
amounts along with constant levels of total EGFR. Thus, the pEGFR/EGFR ratio 
inversely correlates with hVps37A levels as outlined in Figure 6A. Next, we 
juxtaposed hVps37A with activated EGFR receptor levels and found elevated pEGFR 
but constant EGFR levels in all hVps37A-deficient clones analyzed. This resulted in a 
significant increase of the pEGFR/EGFR ratio (Pearsons C=0.915, p<0.011). These 
observations suggested that activated EGFR accumulated within hVps37A–deficient 
cells, secondary to defects in cytoplasmic receptor degradation. We further aimed to 
define the intracellular compartment harboring aberrantly retained pEGFR protein. 
Therefore, ovary cells were grown on coverslips and probed with an anti-EGFR 
antibody (Figure 6B). In the control cell lines, the pEGFR was located mainly at the 
cell membrane (SK-OV-3) or hardly detectable. In contrast, in both hVps37A-deficient 
cell lines, pEGFR was detected at much higher levels in the cytoplasm (Figure 6B). 
To verify our observations in a set of standard cell lines (of ovarian and mammary 
origin), we quantified hVps37A, (p)EGFR and (p)HER2 by immunoblot analysis and 
plotted the ratios of activated to total receptor versus hVps37A (Figure 6C). No 
significant association between hVps37A and EGFR (r = 0.111; p=0.695) was found, 
yet we observed a significant (p<0,01) reciprocal correlation between hVps37A and 
pEGFR protein expression (r = -0.683; p=0.007) as well as between hVps37A and 
pEGF/EGFR protein ratio (r = -0.707; p=0.005). Moreover, a statistically weak 
correlation was found between hVps37A and pHER2 protein expression, which did 
not reach a significance level (data not shown). This may be explained by the fact 
that many of the cell lines were negative for pHER2 and could, therefore, not be 
included in the statistical analysis. These observations led to the conclusion that the 
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observed receptor accumulation was caused by defects in endosomal protein 
degradation. Therefore, we studied the dynamics of pEGFR degradation in wild-type 
and hVps37A-deficient MDAH and SK-OV-3 cells. Upon incubation in serum-free 
media, cells were stimulated with the 100 ng/ml EGF for 15 min to achieve maximal 
receptor activation, followed by re-incubation in serum-free media. At defined time 
points, cells were harvested, proteins prepared, and pEGFR expression was 
determined by Western blotting (Figures 6D, E); pEGFR degradation was 
significantly impaired in both HCRP-1 deficient cell lines compared with control cells. 
Interestingly, the EGFR degradation process of the SK-OV-3 cell line was even 
stronger inhibited compared to the MDAH cell line. 
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Fig. 6. Receptor Accumulation is Caused by a Defective Degradation Process 
in Case of Low hVps37A Levels 
(A) hVps37A, EGFR and pEGFR amounts were determined in various stable clones 
in the MDAH and SK-OV-3 cell lines by Western blotting. White columns indicate 
hVps37A expression; blue columns indicate the ratio of pEGFR to EGFR.  
(B) MDAH and SK-OV-3 cells were fixed on chamber slides, incubated with a 
pEGFR-specific primary antibody and a TRITC-labeled secondary antibody, 
followed by analysis on a fluorescent microscope.  
(C) hVps37A, EGFR and pEGFR amounts were determined in 15 ovarian and 
breast cancer cell lines by Western blotting. hVps37A expression (y-axis) was 
plotted versus pEGF/EGFR ratio (x-axis) on a scatterplot and a trendline was 
calculated        (R-Square=0.52). Statistical significance was proved by Pearson 
Correlation (-0.719) with a p-value of 0.003. 
(D, E) MDAH and SK-OV-3 cells were starved in minimal medium for 24 hours, 
followed by stimulation with 100ng/ml EGF for 15 min and protein harvesting at 
defined points in time as indicated in minutes. Remaining activated receptor levels 
(pEGFR) after different time spans were determined by Western blotting, (Co 
Nonsense Control, KD hVps37A knock-down). 
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3.1.3.5 hVps37A Interferes with EGFR Signal Transduction and is Crucial for 
Anti-EGFR Antibody Treatment  
 Characterizing the compensatory changes in EGFR signaling upon hVps37A-
knock-down might shed further light on the role of hVps37A in ovarian 
carcinogenesis. To achieve this, the relative activation of selected ERBB-signalling 
pathways upon anti EGFR treatment was analyzed in control versus HCRP-1 
deficient cells. Not surprisingly, and consistent with our previous findings, hVps37A 
knock-down was associated with a potent phosphorylation of ERK1/2 (Figures 7A, 
B). This effect was reversed by treating the cells with an EGFR antibody (Cetuximab) 
or tyrosine kinas inhibitor (Lapatinib), reducing pERK1/2 to basal levels observed in 
control cells. Unlike ERK activation, Akt inducibility was not impaired by hVps37A-
knock-down. Intriguingly, the inhibitory effect of Cetuximab on AKT-activation was 
lost upon hVps37A knock-down. This pinpointed towards the fact, that cytoplasmic 
EGFR degradation is crucial for Cetuximab-dependent inhibition of Akt 
phosphorylation. In contrast to this, our data suggested that Lapatinib acts 
independently of hVps37A.  
Dysfunctional activation of ERK- and AKT- signal transduction is often 
reflected by changes in cellular proliferation. Therefore, we determined the 
proliferation rates of SK-OV-3 and MDAH cell lines (Figures 7C, D). Control cells and 
induced hVps37A-deficient SK-OV-3 cells exhibited comparable proliferation 
characteristics (25.5 versus 24.9 hours, respectively). In MDAH cells, the hVps37A 
knock-down caused a negligible increase in cellular proliferation. Taken together, 
these results argued for a limited impact of hVps37A onto cellular proliferation under 
in vitro conditions. In contrast, incubation with Cetuximab significantly decreased the 
proliferation potential of both cell lines, whereas the respective hVps37A-deficient 
cells remained unaffected. This underscored the notion that the presence of 
hVps37A is essential for proper degradation of the receptor-antibody complex. In 
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contrast, EGFR/HER2 inhibition by Lapatinib significantly reduced the proliferation of 
SK-OV-3 and MDAH cells irrespective of hVps37A expression levels (Figures 7C, D). 
These results were confirmed by a CellTiter-Blue assay as independent method (data 
not shown).  
Overall, we suggest hVps37A as novel biomarker potentially guiding future 
therapies in RTK-driven cancers. In order the substantiate our clinical data, we 
further provided some functional insight into hVps37A dependent receptor decay 
mechanisms, leading to a better comprehension of the ESCRT mediated degradation 
process and its implications for tumor biology.  
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Fig. 7. hVps37A Depletion Confers Cetuximab Resistance Based on 
Sustained Akt Pathway Activation 
hVps37A-silenced and control cell lines (SK-OV-3 (A), MDAH (B)) were incubated 
with either 20µg/ml Cetuximab (C), or 4µM Lapatinib (L) for 24 hours, or remained 
untreated (U). Protein levels of important key players of EGFR downstream 
pathways (pAKT, AKT, pERK1/2, ERK1/2) were determined by Western blotting.  
(C, D) Proliferation was estimated by subsequent seeding of 2x105 cells in 
triplicates into 6 wells. Cell number was determined every 48 hours by a CASY cell 
counter. This procedure was performed for 8 days overall. Doubling time (dt) was 
calculated and depicted as 1/dt. The untreated control cell lines were set 1 and 
served as reference. The columns indicate the mean of three independent 
experiments; error bars represent +/-SEM. 
 
3.1.4 Discussion 
Positive regulation of ERBB RTK family isoforms is often associated with tumor 
development and progression. One mechanism leading to hyperactivation of ERBB 
receptors is defective receptor degradation. During this process, activated receptors 
are translocated to the limiting membrane of sorting endosomes where they are 
recognized by four major protein sorting complexes (ESCRT 0-III), internalized into 
endosomes, and degraded upon fusion with the lysosomal compartment(Bache et al., 
2004b; Kirisits et al., 2007). In this study, we could demonstrate for the first time that 
hVps37A, a member of the ESCRT-I complex, is of pivotal importance for ERBB 
receptor degradation process, has significant impact on the survival of OC patients 
harboring ERBB overexpressing tumors, and, thus, constitutes a potential novel 
biomarker with prognostic and potentially therapeutic relevance. 
Various tumor-specific genomic aberrations were mapped recently by 
systemic approaches. The gene of hVps37A is located on the short arm of 
chromosome 8, one of the most frequently altered regions in human cancer. Within 
8p, chromosomal band 22 is a particular deletion hot spot suggesting the residence 
of potential tumor suppressor genes (TSG) in this area. On 8p22, the most accurately 
characterized TSG is DLC1, a Rho GTPase-activating protein identified by a deletion 
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mapping approach and characterized in hepatocellular carcinoma, but most probably 
playing a role in several cancer types (Durkin et al., 2007; Xue et al., 2008). Further 
cancer relevant genes are predicted in the area. Being located also in this very 
genomic region, hVps37A is an intriguing candidate TSG, in particular for cancers 
which are driven by oncogenic signals mediated by ERBB receptors. 
While we could not detect mutations in the coding region of hVps37A 
(unpublished results), we observed hVps37A expression to be significantly reduced 
in primary OC, indicative of a negative selection pressure against hVps37A 
expression. Consistently, depleted hVps37A levels were associated with a more 
aggressive disease, leading to an unfavorable prognosis for patients with ERBB-
overexpressing tumors. For low hVps37A levels, survival analysis revealed an 
increased probability to die also when corrected for FIGO, grade, and histology of the 
tumors. To understand this observation on a molecular level, we decided to further 
elucidate the biological implications of hVps37A expression levels in human OC 
samples. EGFR is an established driver of ovarian cancer development and a 
putative target of hVps37A (Bache et al., 2004a; Lafky et al., 2008). Consequently, 
we quantified activated and total EGFR-, as well as hVps37A protein levels, in 23 
ovarian and breast cancer cell lines, and blotted hVps37A expression against the 
ratio of pEGFR to EGFR, resulting in a significant indirect correlation. Consistent with 
previous studies (Bache et al., 2004a), these data indicate that hVps37A is involved 
in protein turnover of EGFR. The same experiment was conducted for HER2, which 
yielded only borderline statistical significance, most probably due to an insufficient 
amount of pHER2 positive cases. 
In order to further confirm the reciprocal relationship between hVps37A and 
pEGFR/pHER2 expression, we generated two stable hVps37A-defective ovarian cell 
line clones (MDAH2774 and SK-OV-3). In each cell line, knock-down of hVps37A 
Results 28
was associated with concomitantly elevated amounts of pEGFR protein expression 
(and pHER2 for the SK-OV-3 cell line). Via immunofluorescent analysis, we could 
confirm that aberrantly degraded pEGFR was retained in the cytoplasm under 
conditions of hVps37A depletion. The kinetics behind this phenomenon was studied 
by analyzing the influence of hVps37A on the time course of EGFR degradation. Not 
surprisingly, the degradation process of the activated receptor was strictly dependent 
on hVps37A expression, as its knock-down resulted in sustained receptor activation 
upon EGF-stimulation. Interestingly, the degradation inhibitions were found to be 
potentiated in the SK-OV-3 compared to the MDAH cell line. This observation may be 
explained by high amounts of HER2 (in SK-OV-3 cells), which is reported to remain 
more stable at the cell membrane than other receptors of the HER family, and can 
confer this property to its dimerization partners (Sorkin and Goh, 2008). 
Due to the cytosolic orientation of the phosphorylated tail of RTKs, receptors 
targeted for endosomal degradation are still signaling competently, an effect which 
may be potentiated by the observed cytoplasmic retention of pEGFR (Pennock and 
Wang, 2003). In fact, we observed a potent phosphorylation of ERK1/2 upon knock-
down of hVps37A. Interestingly, we received no concomitant increase in cellular 
proliferation. However, there is accumulating evidence that MAPK activation can lead 
to different responses dependent on the cellular background or intensity and duration 
of the signal (Lee et al., 2000; Miaczynska et al., 2004; Tang et al., 2002; Zhang and 
Liu, 2002).  
These observations were highly reminiscent of the phenotype of Tsg101, 
another component of the (ESCRT-I) protein complex. It has been reported that the 
endosomal degradation of EGFR is impaired in Tsg101-deficient cells (Raiborg et al., 
2008). In addition, non-functional Tsg101 causes EGFR accumulation within the 
cytoplasm (Lu et al., 2003), arguing for non-functional ESCRT-I complexes under 
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conditions of HCRP-1 knock-down. In line with this, we assume that hVps37A might 
constitute a novel tumor suppressor in multiple tumor entities, as has been reported  
for the whole ESCRT-I complex (Tanaka et al., 2008).  
Collectively, our data raised the following question: If hVps37A levels 
significantly regulate the cellular localization of known pro-oncogenes like activated 
EGFR and HER2, does it possess the potential to modulate their established impact 
on disease progression? This question was addressed by immunostaining TMAs 
comprising 125 primary ovarian tumors against hVps37A, EGFR, and HER2. 
Intriguingly, we found that hVps37A protein levels significantly altered the prognostic 
impact of EGFR and HER2 expression, which is well described in the literature 
(Crijns et al., 2006; Pils et al., 2007a). Under conditions of low hVps37A expression, 
both EGFR and HER2 expression levels highly influenced patients' prognosis, an 
effect which was completely abrogated under conditions of high hVps37A 
expression. This observation may be explained by the notion of a disproportionately 
high number of activated RTK, which are unable to be counterbalanced by reduced 
hVps37A-mediated degradation.  
Although most studies reported EGFR or HER2 overexpression to be 
associated with an unfavorable prognosis of ovarian cancer patients, the results were 
often inconsistent (Crijns et al., 2003). Multiple marker testing would thus be 
beneficial to obtain a more reliable and accurate picture of the tumor. In this work, we 
established hVps37A as a potential tumor suppressor, significantly modifying the pro-
cancerogenic effects of EGFR/HER2 overexpression. If these results can be 
confirmed in more comprehensive clinical studies, hVps37A-testing should be 
included – besides EGFR- and HER2 testing – in the characterization of ovarian 
cancer. 
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Apparently, individual tumor cells enhance their selective advantage in the 
course of disease progression via down-regulating hVps37A. This effect would lead 
to an increase in disease aggressiveness and an unfavorable prognosis. Such 
tumors should be prone to a disruption of this pathway by a therapy against EGFR, 
which is a promising molecular target for cancer therapy using monoclonal antibodies 
or small molecule tyrosine kinase inhibitors (TKIs). In order to assess the influence of 
hVps37A on those kinds of therapy, SK-OV-3 and MDAH-2774 cell lines were 
examined for their susceptibility to an EGFR antibody (Cetuximab) and a TKI 
(Lapatinib), respectively. While there are various mechanisms leading to resistance 
against anti-EGFR- therapies, including autocrine EGFR activation, mutation of 
downstream signaling effectors, and cross-activation of alternative RTKs, a recently 
published study added an additional twist: Cancer cell lines made resistant to 
Cetuximab by long term exposure developed increased EGFR levels based on 
defects in receptor degradation (Wheeler et al., 2008). The genetic knock-down of 
hVps37A and the resulting resistance to Cetuximab in our model confirm and offer a 
molecular mechanism of this important finding. Cetuximab is a widely used 
therapeutic antibody directed against EGFR. It down-regulates EGFR signal 
transduction by various mechanisms, such as competing for extracellular EGFR 
ligands, forced receptor internalization, and degradation or induction of an immune 
response to the Fc-region in vivo (Peipp et al., 2008). Further, in addition to the 
antagonistic effects, Cetuximab also possesses the potential to trigger EGFR 
activation and dimerization prior to its down-regulation (Mandic et al., 2006; Yoshida 
et al., 2008). As described above, our results suggest that limited amounts of 
hVps37A rather inhibit EGFR degradation, leading to cytoplasmic receptor 
accumulation and hyperactivation of the MAPK pathway. Following incubation with 
Cetuximab, MAPK pathway activation (ERK1/2) was reduced, yet we observed a 
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potent compensatory activation of the AKT-pathway in hVps37A-deficient cell lines, 
arguing for functional signaling capacity of the EGFR-Cetuximab complex within the 
cytoplasm. The cellular phenotype of this finding is resistance to Cetuximab-related 
inhibition of proliferation. Our findings are in line with a recent study of Wheeler et al., 
who generated a Cetuximab-resistant NSCLC cell line. The latter was found to harbor 
defects in EGFR internalization and degradation, suggesting that these mechanisms 
are crucial for Cetuximab to be effective (Wheeler et al., 2008). Yet, the notion of 
constitutive PI3K activation by endosomally located EGFR contradicts a study which 
reported that PI3K activation is restricted exclusively to the plasma membrane 
(Haugh and Meyer, 2002).  
In contrast to Cetuximab, Lapatinib directly blocks EGFR activation by 
targeting the ATP-binding domain. This leads to defective EGFR-dependent signal 
transduction independently of ESCRT mediated receptor down-regulation (Xia et al., 
2002). This is in line with our observations, that PI3K/AKT and MAPK pathways, as 
well as cell proliferation, were inhibited by Lapatinib irrespective of hVps37A 
expression levels.  
Overall, we identified hVps37A as a keyplayer for tumor development being 
essential for the degradation of RTK oncogenes. We elucidated important aspects of 
the molecular mechanism and showed the clinical relevance of hVps37A to establish 
it as a novel TSG and prognostic biomarker in ovarian cancer and beyond. 
In order to further examine the clinical significance of our findings, it would be 
beneficial to assess the impact of hVps37A expression onto the survival of patients 
sensitive to Cetuximab therapy (or other monoclonal antibodies against EGFR) or 
not. If an association between hVps37A expression and the efficacy of anti-EGFR 
therapy would be confirmed in a clinical setting, hVps37A could be considered as a 
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novel predictive marker to better select patients for the application of monoclonal 
antibodies in targeted therapies against EGFR- overexpressing tumors. 
 
3.1.5 Material and Methods 
 
3.1.5.1 Patient Material  
 
For mRNA expression analysis, ovarian tumor samples from primary tumors with 
complete clinical documentation were obtained from patients who underwent optimal 
debulking surgery at the Charité Hospital in Berlin, Germany (Table 1). Epithelial-
enriched normal ovarian and benign cyst samples came from patients diagnosed 
without malignant disease at the Medical University of Vienna. In total, 21 normal 
ovarian samples, 88 primary tumors, and 38 recurrent tumors, mostly intraperitoneal 
metastases after primary surgery followed by platin based chemotherapy, were 
assessed. Informed consent for the scientific use of biological material was obtained 
from all patients in accordance with the requirements of the ethics committee of the 
individual institution.The patient material for the tissue microarray (TMA) is described 
in detail in Table 1. Microarrays were composed by taking core needle “biopsies” 
from specific locations in the pre-existing paraffin-embedded tissue blocks and re-
embedding them in an array master block, using techniques and an apparatus 
developed by Beecher Instruments Inc., Micro-Array Technology (Sun Prairie, WI, 
USA). To achieve good representation of the tumor, three biopsies of tumor material 
were selected from each patient. None of the patients with borderline tumors died 
during the follow-up time and were excluded from the survival analysis. 
3.1.5.2 Data Analysis and Statistics 
In order to compare hVps37A expression between primary tumors, recurrent 
tumors, and normal controls, a Mann-Whitney U test was performed. The potential 
Results 33
influence of hVps37A expression on overall survival is presented in plots of the 
corresponding Kaplan-Meier estimates and quantified using Cox regression, first with 
a univariate model and then adjusted for grading, staging according to FIGO, and 
morphologic subtype of the tumor samples. Ninety-five percent confidence intervals 
were calculated. hVps37A was dichotomized at the median. Histology was 
dichotomized into serous and nonserous tumors. Tumor stage and grade were used 
as continuous variables. P-values ≤0.05 were considered to be statistically 
significant. 
In the tissue microarray, staining intensities were analyzed by two independent 
persons and classified in 0 (missing expression), 1 (low expression), 2 (medium 
expression), and 3 (high expression). Equal to the mRNA expression analysis 
experiment, hVps37A was dichotimized into two groups at the median. For EGFR 
and HER2, results of triplicates and both interpretations were averaged and re-scaled  
(0-3). HER2, according to standard procedures for breast cancer, was divided into 
two groups with low (0, 1) or high (2, 3) expression. Since 40% of the tumor samples 
stained negatively or very weakly positively for EGR, we divided into two groups of 
positive and negative EGFR expression. Kaplan-Meier plots and survival analysis 
were calculated as described above. All statistical analyses were performed on SPSS 
15 (Chicago, IL, USA). 
3.1.5.3 RNA Isolation, cDNA Synthesis and Quantitative RT-PCR 
Total RNA from cell lines was prepared with the RNeasy Mini Kit (Qiagen, 
Hilden, Germany) and quality and quantity assessed on RNA Nano Chips (Lab-on-a-
Chip, Agilent Technologies, Palo Alto, CA, USA). All steps were accomplished 
according to the manufacturers' protocols.  
cDNA was synthesized from 1µg total RNA using the DuraScript RT-PCR Kit 
(Sigma-Aldrich, Saint Louis, MO, USA) in a volume of 20µl and subsequently diluted 
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to a total volume of 100µl. The following Assay-on-Demand™ probes were selected 
for TaqMan real-time PCR: FLJ32642, Hs00329751_m1 and beta 2-microglobulin 
(B2M), Hs99999907_m1, HPRT1 and GAPDH (Applied Biosystems, Foster City, CA, 
USA). The real-time PCR reaction mix was composed of 10µl TaqMan® Universal 
PCR Master Mix (Applied Biosystems) supplemented with 2µl of the obtained cDNA, 
1µl of the probe and 8µl of ddH2O to a total volume of 20µl. The reaction was realized 
on the 5700 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) 
with cycle conditions as follows: Initially 50 °C for 2 minutes and 95 °C for 10 
minutes, followed by 40 cycles of 95 °C for 15 seconds and 60 °C for 1 minute. 
Relative expression was calculated from the threshold cycles (Ct) obtained with the 
GeneAmp 5700 SDS Software v1.3 (Applied Biosystems) as follows: 2^–[(Ctgene 
mean of duplicated probes – Ctgene mean of duplicated calibrator) – (CtB2M mean of 
duplicated probes – CtB2M mean of duplicated calibrator) ].  
3.1.5.4 Silencing of hVps37A in Different Cell Lines 
The SK-OV-3 cell line was cultured equally to the MDAH-2774 cell line except 
for the use of McCoy´s medium. For applying the Tet-Off inducible system, founder 
cell lines were generated by transfecting SK-OV-3 cells with the pTet-Off vector 
(neor) encoding a tetracyclin repressible transactivator (tTA). Resistant colonies were 
selected with 200 µg/ml G418 and characterized by transient transfection with the 
luciferase reporter plasmid (pTRE-Luc), whose promoter is induced by the 
transactivator. Luciferase activity in the presence and absence of tetracycline was 
measured to identify cells with maximal promoter inducibility. Highest induction was 
92-fold. These two founder cell lines were used to establish cells inducible for 
hVps37A-specific shRNA constructs (Open Biosystems; #V2HS_21202, 
#V2HS_21203), which were cloned into the SIN-TREmiR30-PIG vector (purr) 
downstream of the tetracycline inducible promoter. Thus, presence of tetracycline in 
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the culture medium would suppress shRNA expression, while its withdrawal would 
induce the knock-down of hVps37A. Puromycin-resistant colonies were isolated in 
the presence of tetracycline, and screened for silencing efficiency of hVps37A by 
qRT-PCR and Western blotting. 
The human ovarian carcinoma cell line MDAH-2774 was cultured in RPMI 
medium with 10% FCS (fetal calf serum), 50 units/ml penicillin G, and 50 μg/ml 
streptomycin sulfate at 37 °C in a humidified atmosphere of 95% air with 5% CO2. 
Three different shRNA constructs complementary exclusively to the hVps37A mRNA, 
in addition to 1 nonsense construct serving as a control, were cloned into the vector 
pSilencer 4.1-CMV neo. Transfection was performed with Lipofectamine 2000 
according to the manufacturers’ protocol (Invitrogen, Carlsbad, CA, USA). Stable 
clones were selected with 700 µg/ml G418, picked, and sub-cultured with 350 µg/ml 
G418. Silencing efficiency was quantified by qRT-PCR and western blot.  
3.1.5.5 Antibody Production 
Since no commercial hVps37A-specific antibodies were available, we 
established a polyclonal peptide antibody against hVps37A. The following peptide 
sequence was selected: MSPYASQGFPFLPPY. Rabbit antiserum raised against this 
peptide sequence was prepared by Eurogentec (Seraing, Belgium). The serum was 
affinity purified on beads containing the selected peptide and tested for its 
applicability in Western blotting and immunohistochemistry.  
3.1.5.6 Protein Preparation and Western Blotting 
The following antibodies were used in the dilution indicated: hVps37A 1:200 
(established as described above); primary antibodies ( EGFR 1:300, pEGFR 1:100, 
HER2 1:200, pHER2 1:200, ERK1 1:5000, ERKk2 1:5000 and beta-actin 1:300) and 
HRP-conjugated secondary antibodies (anti-goat 1:10000 and anti-rabbit 1:10000) 
were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA) AKT and 
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pAKT were purchased from Cell Signaling Technology (Beverly, MA, USA). Upon 
treatment, cells were lysed and protein was prepared with RIPA+ buffer; protein 
concentration was determined by a standard Bradford absorbance assay (Sigmal 
Aldrich, Saint Louis, MO, USA). Equal amounts of proteins (30µg) were separated by 
SDS-PAGE, blotted on PVDF membranes (GE Healthcare, Buckinghamshire, UK), 
incubated with the appropriate primary antibody, and visualized via HRP-conjugated 
secondary antibodies and treatment with the ECL chemiluminescent detection 
system (GE Healthcare, Buckinghamshire, UK).  
3.1.5.7 Immunohistochemistry  
After deparaffinization and rehydration, the samples were treated with 0.3% 
H2O2/PBS (pH 7.4) for 10 minutes to quench endogenous peroxidase activity and 
blocked with serum of the secondary antibody diluted 1:50 in PBS. Primary 
antibodies against EGFR produced in rabbit and hVps37A were diluted 1:100 in 
serum/PBS and applied on the samples for 1 hour. HER2 was stained using the 
DAKO HercepTest. The secondary antibody against rabbit was applied for 30 
minutes. After visualization with DAB+ (Dako, CA, USA) and counterstaining with 
hematoxyline/eosin, the slides were mounted in Eukitt (O. Kindler GmbH, Freiburg, 
Germany) and analyzed on an Olympus BX50 upright light microscope (Olympus 
Europe, Hamburg, Germany) equipped with the Soft Imaging system CC12. 
For the tissue microarray, each sample was treated in an identical manner and 
the entire cohort was analyzed in one batch on three slides. Reagent conditions, 
incubation times and temperatures, and antigen retrieval (if necessary) were held 
identical for each case as previously described.  
3.1.5.8 Fluorescence Microscopy 
Cells were seeded on chamber slides, grown for 48 hours, fixed with 4% 
paraformaldehyde for 15 minutes, and permeabilized with 0.1% Triton X-100. The 
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subsequent staining procedure was performed as described for immuno-
histochemistry. The cells were incubated with the primary antibody (goat) directed 
against pEGFR (1:100) for 1 hour. TRITC-conjugated secondary antibody (1:100) 
was applied on the cells for 45 minutes and counterstain of the nuclei was realized by 
DAPI (Roche, Manchester, England) or Quinacrine. Afterwards the cells were 
analyzed on a fluorescence microscope (Nikon Eclipse 800) equipped with a Nikon 
DS-R1 camera by using the NIS-Elements software.  
3.1.5.9 Proliferation Assays  
2x105 SK-OV-3 (with and without doxycyclin) and MDAH (hVps37A silenced, 
nonsense control and wildtype) cells were seeded in 6-well plates in media 
complemented with 10% FCS and treated with 20 µg/ml Cetuximab (Merck, 
Whitehouse Station, NJ, USA), 4 µM Lapatinib (GlaxoSmithKline plc. London, UK), or 
were mock-treated. To maintain the logarithmic phase, cells were split at intervals of 
48 hours, along with the determination of the cell number by a CASY cell counter 
(Innovatis AG, Bielefeld, Germany). This procedure was performed in triplicate over a 
time-span of 6 days and confirmed by a replication of the whole experiment. From the 
obtained data, doubling times (dt) were calculated and depicted as dt-1. 
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3.2 Project 2: Methylation of N33 (TUSC3) Independently Predicts 
Ovarian Cancer Patient Outcomes, Caused by Altered N-
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3.2.1 Abstract 
BACKGROUND Treatment decisions in ovarian cancer therapy are based on tumor 
stage, tumor grade, and residual tumor size after debulking surgery, but only few 
prognostic markers are well established. Here, we present the promoter methylation 
status of TUSC3, a gene on chromosome 8p22, as a new molecular marker and a 
putative therapeutic target for ovarian cancer.  
METHODS TUSC3 mRNA expression was determined by quantitative RT-PCR in 
102 ovarian cancer specimens, followed by promoter-methylation studies via 
methylation specific PCR. Reconstitution of TUSC3 in vitro was used for subcellular 
localization and functional analysis. 
RESULTS TUSC3 expression was significantly down-regulated by epigenetic 
regulation in ovarian cancer samples compared to controls (P<0.001). At the time of 
the initial diagnosis, 29.4% (30/102) of patients had a methylation of the TUSC3 
promoter vs. none of the controls (P=0.003). Methylation of the TUSC3 promoter had 
a strong influence on progression-free (HR 2.17, P=0.024) and overall survival (HR 
4.11, P=0.008) which was independent from other prognostic factors. In vitro 
reconstitution of TUSC3  into ovarian cancer cells demonstrated its localization to the 
endoplasmatic reticulum and triggered cell appearance changes along with 
decreased proliferation and increased migration. These changes go along with 
altered N-glycosylation patterns of integrin ß1 in TUSC3 reconstituted cells, resulting 
in decreased adhesion to collagen I. 
CONCLUSIONS Epigenetic down-regulation of TUSC3 is a frequent event in ovarian 
cancer. We show for the first time that TUSC3 is involved in glycosylation of proteins 
and acts as a tumor suppressor gene with strong and independent impact on ovarian 
cancer patient prognosis.  
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3.2.2 Introduction 
Epithelial ovarian cancer is the most lethal gynecologic malignancy and with 
about six percent the fourth most frequent cause of cancer related death in women in 
industrialized countries. Estimates indicate that one in 70 women will develop ovarian 
cancer in her lifetime, with a median survival rate of 4.5 years. A recent cancer 
statistic reported an estimated 22,200 new cases and 16,210 deaths per year in the 
United States (Jemal et al., 2005).  
Early diagnosis represents a major challenge in the treatment of this disease 
and more than three quarters of cases are diagnosed in late stages (FIGO III and IV). 
These patients need intensive multimodal therapy consisting of optimal debulking 
surgery and adjuvant chemotherapy. 
Currently used prognostic factors include staging, grading, and the size of 
residual tumor after initial cytoreductive surgery (Holschneider and Berek, 2000; van 
der Burg, 2001). Apart from Cancer Antigen 125 (CA-125) (Makar et al., 1992) there 
are no other specific diagnostic and prognostic molecular markers available in clinical 
practice. Promoter methylation patterns of tumor suppressor genes (TSGs) hold a 
particular promise as new molecular markers. They can give insight into the biology 
of a tumor and in contrast to a gene or protein expression analysis, they can be 
easily detected by PCR-based methods in tumor material as well as in body fluids 
(Das and Singal, 2004; Jones and Baylin, 2002; Laird, 2003). 
TUSC3 (tumor suppressor candidate 3), originally named N33, was identified 
as a potential TSG in prostate cancer located on chromosome band 8p22 (Bova et 
al., 1996; MacGrogan et al., 1996). Known homozygous deletions (HDs) of this 
region in pancreatic (Bashyam et al., 2005; Levy et al., 1999) and prostate cancer 
cell lines (Arbieva et al., 2000; Bova et al., 1993) contain no other cancer related 
genes except for TUSC3, but mutations of the TUSC3 coding sequence are rarely 
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found (Pils et al., unpublished data). Systematicly screening the region on 8p22, we 
recently showed TUSC3 to be significantly down-regulated in ovarian cancer tissues 
and of potential prognostic value (Pils et al., 2005a).  
Molecular function of the TUSC3 gene product remains largely unknown. TUSC3 
shares a high sequence homology with OST3p, a subunit of the 
oligosaccharyltransferase complex involved in N-glycosylation of proteins in 
Saccharomyces cerevisiae (Kelleher and Gilmore, 2006; Kelleher et al., 2003a),  
suggesting TUSC3 might have a similar function in human cells. 
Glycosylation is a ubiquitous posttranslational modification of eukaryotic 
proteins, preferentially of those with contact to the extracellular matrix. In general, it 
protects proteins from degradation but can also modulate their function (Ohtsubo and 
Marth, 2006) as well as their immunogenicity (Galonic and Gin, 2007). Changes in 
glycosylation patterns in tumor cells are well described, but functional knowledge 
about their origin is limited (Dennis et al., 1999; Kobata and Amano, 2005). 
Alterations of relative amounts of sialic acids moieties, which can be generally 
found at the terminus of oligosaccharide chains on several glycoproteins, were 
shown to be associated with some cancer cells propreties, such as invasiveness and 
metastatic potential (Collard et al., 1986; Dennis et al., 1987; Yogeeswaran and Salk, 
1981). Increased enzymatic activities of proteins directly involved in sialylation 
(Kakugawa et al., 2002), or the availability of potential sialylation sites determined by 
the branching of N-glycans are considered to be crucial for these effects. Well known 
targets for differential sialylation in tumor cells are, among others, growth factor 
receptors (Lau et al., 2007) and structural proteins with impact on cell-cell interaction 
and extra cellular matrix binding, such as integrin ß1 (Seales et al., 2003). 
In this report we for the first time identify an epigenetic mechanism inhibiting 
TUSC3 expression, which also has a high independent prognostic value in ovarian 
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cancer. Additionally, we show in vitro that decreased TUSC3 expression alters the N-
glycosylation pattern of proteins in ovarian cancer cell lines. Taken together, we 
present the first evidence that a protein involved in N-glycosylation of proteins acts as 
a tumor suppressor gene with a major impact on patient survival in ovarian cancer.  
 
3.2.3 Material and Methods 
3.2.3.1 Patient Material and Cancer Cell Lines 
Ovarian tumor samples were obtained from patients who underwent optimal 
debulking surgery at the Charité Hospital Berlin, Germany. Epithelial-enriched normal 
ovarian and benign cyst samples came from patients diagnosed without malignant 
disease at the Medical University of Vienna. In total, 20 benign ovarian samples and 
102 primary tumor samples were assessed (Table 3). 84% of patients were treated 
with a platin-based first line chemotherapy regime. Informed consent for the scientific 
use of biological material was obtained from all patients in accordance to the 
requirements of the ethical committee of the individual institutions. The panel of 38 
ovarian cancer cell lines was described earlier (Pils et al., 2005a). 
Table 3. Clinicopathologic Characteristics of Patients 
A) Benign ovarian samples (corresponding mRNA samples) 20 (20) 
 Age at operation [years]   
  Mean ± SD 49.9 ± 11.8 
  7 Normal ovaries, mean age [yrs]:  51.6 
  13 Benign cysts, mean age [yrs]:  49.0 
  
B) Tumor samples (corresponding mRNA samples) 102 (99) 
 Age at diagnosis [years]  
  Mean ± SD  58.3 ± 11.0 
 Histology (1 (1.0%∞) missing)  
  Serous 79 (77.4%∞) 
  Endometrioid 10 (9.8%) 
  Mucinous 5 (4.9%) 
  Clear cell 2 (2.0%) 
  Other 5 (4.9%) 
 FIGO (2 (2.0%) missing)  
  I 17 (16.7%) 
  II 10 (9.8%) 
  III 51 (50.0%) 
  IV 22 (21.6%) 
 Grading (1 (1.0%) missing)  
  1 2 (2.0%) 
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  2 48 (46.1%) 
  3 51 (50.0%) 
 Residual disease after initial surgery (3 (2.9%) missing)  
  ≤ 1cm 86 (84.3%) 
  > 1cm 13 (12.7%) 
 First line chemotherapy (3 (2.9%) missing)  
  Carboplatin and Taxol  63 (61.8%) 
  Carboplatin, Taxol and Gemcitabine 17 (16.7%) 
  Carboplatin or Taxol monotherapy 3 (2.9%) 
  Carboplatin and other 8 (7.8%) 
  Other 3 (2.9%) 
  No 5 (4.9%) 
 Response to first line chemotherapy (16 (15.7%) missing)  
  NED‡ 6 (5.9%) 
  NC† 3 (2.9%) 
  PD† 12 (11.8%) 
  PR† 5 (4.9%) 
  CR‡ 43 (42.2%) 
  Duration of response  
   0 – 6 months†,‡ 6 (5.9%) 
   6 – 12 months‡ 5 (4.9%) 
   > 12 months‡ 6 (5.9%) 
 Remissions/progressive disease (3 (2.9%) missing)  
  w/o remission 49 (48.0%) 
  w/ remission 33 (32.4%) 
  Progressive disease 17 (16.7%) 
∞Percent based on 102 tumor samples. 
†Non-responders to first line chemotherapy. 
‡Responders to first line chemotherapy. 
3.2.3.2 DNA and RNA Isolation 
Genomic DNA from about 15 mg of frozen tissue or cell lines was prepared 
with the DNeasy Tissue Kit (Qiagen, Hilden, Germany) and quantified with the 
PicoGreen dsDNA Quantitation Kit (Molecular Probes, Inc., Eugene, OR, USA). Total 
RNA from frozen tissues was extracted with the Agilent Total RNA Isolation Mini Kit 
(Agilent Technologies, Palo Alto, CA, USA). Total RNA from cancer cell lines was 
prepared with the RNeasy Mini Kit (Qiagen, Hilden, Germany) and quality/quantity 
assessed on RNA Nano Chips (Lab-on-a-Chip, Agilent Technologies, Palo Alto, CA, 
USA).  
 
3.2.3.3 Methylation-specific PCR (MSP) and DNA-Demethylation 
Bisulfite treatment of 1 µg of genomic DNA was done as described previously 
(Horak et al., 2005). PCR was performed with 25 ng bisulfite treated DNA, primers 
published by Xu et al. (Xu et al., 2004) and primers of own design (sequence will be 
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provided upon request), and AmpliTaq Gold (Applied Biosystems, Foster City, CA, 
USA). Bisulfite sequencing (primer sequences upon request) was performed directly 
with the PCR products purified with the QIAquick PCR Purification Kit (Qiagen, 
Hilden, Germany). DNA demethylation of a cancer cell line was performed by a 72 h 
treatment with 1 or 2.5 µM 5-aza-2’-deoxycytidine (Sigma-Aldrich, St. Louis, MO, 
USA) in cell culture medium and relative TUSC3 expression was evaluated by 
quantitative real-time RT-PCR. 
 
3.2.3.4 cDNA Synthesis and Quantitative RT-PCR 
cDNA was synthesized from 1 µg DNase I-digested total RNA using the 
DuraScript RT-PCR Kit (Sigma-Aldrich, Saint Louis, MO, USA). TaqMan real-time 
PCR was performed and relative expression was calculated (given as arbitrary ‘ratio 
units (ru)’) as described (Pils et al., 2005a) using the following Assay-on-Demand™ 
probes: TUSC3, Hs00185147_m1 and beta 2-microglobulin, Hs99999907_m1 
(Applied Biosystems, Foster City, CA, USA). 
 
3.2.3.5 Establishment and Analysis of Two Cell Line Models 
Cells were cultivated in medium (H134: DMEM + 25 mM HEPES (pH 8.0), MIA 
PaCa-2: α-MEM) with 10% FCS (fetal calf serum), 50 units ml-1 penicillin G, and 50 
µg ml-1 streptomycin sulfate at 37°C in a humidified atmosphere of 95% air with 5% 
CO2. For the reconstitution of TUSC3 expression, the CDS of the IMAGE clone 
(BC010370 in pDNR-LIB) was cloned into the expression vector pLP-IRESneo.  For 
the TUSC3-FLAG fusion protein the FLAG peptide was cloned in frame behind the C-
terminus of TUSC3. The empty vector pLP-IRESneo was used as a control (Co). 
Transfections were performed with lipofectamine 2000 (Invitrogen), stable clones 
were selected with G418 (H134: 700 µg ml-1, MIA PaCa-2: 800 µg ml-1) and 
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subcultured with half of these concentrations. The mRNA expression was determined 
by qRT-PCR as described above. In H134 (an ovarian cancer cell line with 
methylated TUSC3) and MIA PaCa-2 (a pancreas carcinoma cell line with a 
homozygous deletion of TUSC3) TUSC3 expression was reconstituted with two DNA 
constructs, one coding for a TUSC3-FLAG fusion protein (TFlag) and one coding for 
a full length TUSC3 cDNA (TUSC3). 
Proliferation rates were determined with growth curves. Migration and invasion 
abilities were measured using in vitro migration (8.0 µm pore size control chambers) 
and invasion assays (BD Matrigel invasion chambers). For the collagen I and BSA 
adhesion assay, cells were incubated on coated 96-well ELISA plates for 30 minutes, 
washed, and remaining cells were quantified with the Cell Titer-Blue® cell viability 
assay (Promega, Madison, WI, USA). For colocalization experiments, subcellular 
fractions (nuclei, mitochondria, lysosomes, microsomes, and cytoplasm) were 
prepared based on a differential centrifugation protocol (1,000, 9,700, 20,200 and 
18,2000 gmax for above organelles, respectively (Graham and Rickwood, 1997)) after 
cell lysis with a Potter pestle. The purity of these fractions was analysed with 
antibodies against marker proteins (nucleoprin p62, cox 5a, none, ribophorin I, and ß-
actin for above fractions, respectively). As primary antibody against FLAG mouse 
monoclonal anti-FLAG M2 antibody (10 µg ml-1, Sigma Aldrich, Saint Louis, MO, 
USA) and as secondary antibody a goat anti-mouse HRP-linked antibody (1:10,000, 
Calbiochem, San Diego, CA, USA) was employed. 
 
3.2.3.6 Immunoblotting, Immunofluorescence, and Immunocytochemical 
Staining 
For immunoblotting, 5 µg proteins of the microsomal fraction and, as a control, 
the same amount of PNGase F digested proteins were separated on a 6% PAA-SDS 
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gel and blotted on a PVDF membrane. The primary antibody was a polyclonal goat 
anti-integrin ß1 antibody (1:1,000, R&D, Minniapolis, MN, USA) and the secondary 
antibody was a donkey anti-goat-HRP-liniked antibody (1:10,000, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA). 
Immunofluorescence staining was performed on formaldehyde-fixed cells with 
antibodies against FLAG (F2555, Sigma Aldrich) and calnexin (polyclonal rabbit 
antibody, personal gift of E. Ivessa) and counterstained with phalloidin (F-actin). For 
a morphological overview, the whole cells were stained with either hematoxylin/eosin 
or phalloidin (F-actin)/DAPI (nuclei).  
For immunocytochemical staining cells on Lab-Tek™ Chamber Slides™ 
(Nagle Nunc International, Rochester, NY, USA) were formaldehyde-fixed and 
permeabilized with 0.5% Triton X-100. Endogenous peroxidase activity and slides 
were blocked with 3% H2O2/PBS and 0.2% fish gelatine, respectively. After 
incubation with polyclonal goat anti-integrin ß1 antibody (1:500, R&D, Minniapolis, 
MN, USA) and biotinylated rabbit anti-goat antibody (1:200, Vector Laboratories, 
Burlingame, CA, USA) or with the biotinylated sialic acid-specific lectin SNA (1:200, 
Vector Laboratories, Burlingame, CA, USA), the streptavidin ABComplex-HRP (ABC-
Kit from Dako, Glostrup, Denmark) was employed and subsequently DAB+ (Dako) 
staining was performed. Finally cells were counterstained with hematoxyline/eosin 
and mounted in Eukitt (O. Kindler GmbH, Freiburg, Germany) (Pils et al., 2007b). 
Microscopy was performed on an Olympus BX50 upright light microscope (Olympus 
Europe, Hamburg, Germany) equipped with the Soft Imaging system CC12. 
 
3.2.3.7 Statistical Analysis 
Continuous variables are presented as mean and standard deviation, 
categorical variables as absolute and relative frequencies. In order to compare 
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frequencies between two or more groups, a Fisher’s exact test or a Fisher-Freeman-
Halton test, respectively, was performed. Mean values and 95% confidence intervals 
for TUSC3 expression were calculated on a logarithmic scale and then transformed 
back to the original scale. In order to compare TUSC3 expression between two or 
more groups a T-test or one-way ANOVA, respectively, was performed using the log-
transformed expression as independent variable. Analogously, the potential influence 
of methylation on TUSC3 expression was investigated using a T-test at the 
logarithmic scale. The potential influence of TUSC3 methylation on progression free 
and overall survival is presented in plots of the corresponding Kaplan-Meier 
estimates and quantified using Cox proportional hazards regression models. As time 
point for progression the date of the documentation of the first relapse or the first 
documentation of the disease progression starting at the time of the first diagnosis 
was used. Univariate Cox models were used to demonstrate the influence of known 
prognostic factors and the potential new prognostic factor. Phenotypical changes and 
changes in binding to collagen- and BSA-coated surfaces of cell lines TUSC3 and 
TFlag were compared each with a control using t-tests with subsequent Bonferroni-
Holm correction. P-values ≤ 0.05 were considered to be statistically significant. All 
computations have been performed using SAS software Version 9.1 (SAS Institute 
Inc., Cary, NC, USA, 2001); graphics were produced using SPSS software Version 
13.0 (SPSS Inc. Headquarters, Chicago, Illinois, USA). 
 
3.2.4 Results 
3.2.4.1 TUSC3 mRNA is Down-regulated in Ovarian Cancer 
TUSC3 mRNA expression was significantly decreased in ovarian cancers 
(n=99, median 0.105 ru) compared to benign ovarian tumors (n=20, median 0.465 ru, 
P<0.001) (Fig. 8A, Table 4). Ovarian cancer cell lines have generally low levels of 
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TUSC3 mRNA, in keeping with their dedifferentiated and highly proliferative 
phenotype. We did not detect any significant differences in TUSC3 expression 
between different age groups, different FIGO stages, or different grades of ovarian 
cancer patients. Interestingly, expression of TUSC3 in the subset of non-serous 
ovarian tumors, which are known to have worse outcomes than the purely serous 
tumors, was significantly lower (uncorrected P=0.037) (Table 4).  
 
Table 4. Comparison of TUSC3 Expression by Clinicopathologic Characteristics 
Clinicopathologic Characteristics Expression of TUSC3 (mean) 
Comparison
(P)  
Benign ovarian samples   
 Mean 0.465  
 CI 0.347-0.623  
   
Tumor Samples (compared to benign ovarian samples)  <0.001† 
 Mean 0.105  
 CI 0.082-0.135  
  Age   
   ≤ 50 0.085 0.299† 
   > 50 0.114  
  Histology   
   Serous 0.121 0.037† 
   Non-serous 0.064  
  FIGO   
   I 0.084 0.764‡ 
   II 0.124  
   III 0.104  
   IV 0.126  
  Grading   
   1 0.068 0.188‡ 
   2 0.135  
   3 0.086  
‡ANOVA (calculated after logarithmic transformation, means and CI are given after back-
transformation to the original scale). 
†T-Test (calculated as above). 
 
3.2.4.2 Methylation of the TUSC3 Promoter and Reconstitution of Expression 
by DNA-Demethylation 
We have previously shown that the mRNA expression of TUSC3 was 
undetectable or at the lower limit of detection in eight out of 38 ovarian cancer cell 
lines (Pils et al., 2005a). TUSC3 promoter was methylated in seven out of these eight 
cell lines, as opposed to four out of thirty methylated cell lines with higher TUSC3 
mRNA levels (Fig. 8B and 8C). We observed a significant link between TUSC3 
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mRNA expression and the promotor methylation status of the respective cell line 
(P<0.001) (Fig. 8A and 8C), pointing towards epigenetic transcriptional regulation of 
TUSC3 by DNA methylation. In order to further investigate the epigenetic regulatory 
mechanism, we treated the ovarian cancer cell line MZ6, which shows low TUSC3 
mRNA levels as well as promoter hypermethylation, with increasing concentrations of 
the demethylating agent 5-aza-2’-deoxycytidine (Aza). Indeed, demethylation of the 
TUSC3 promoter with Aza led to an induction of TUSC3 mRNA after 72h (Fig. 8D).  
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Fig.8. A) Box plots of the expression of TUSC3, given in arbitrary units (ratio units) in 
benign ovarian tissue samples, ovarian tumor samples, and ovarian cancer cell lines 
(left) and expression of TUSC3 subdivided in unmethylated (U) and hypermethylated 
(M) fractions (right). Statistical analysis: T-test on logarithmic scale. B) 
Representative ethidium bromide agarose-gels showing methylation-specific PCR 
products of nine benign ovarian tissue samples (top), nine ovarian tumor samples 
(center), and nine ovarian cancer cell lines (bottom). We used Sss I (CpG methylase) 
methylated human DNA and H2O for positive and negative controls, respectively. C) 
Expression of TUSC3 in 38 ovarian cancer cell lines. Cell lines with silenced TUSC3 
expression are marked with arrows and cell lines with methylation-specific PCR 
products are marked with asterisks. D) Reconstitution of TUSC3 expression after 72-
hour incubation with 1 or 2.5 µM 5-aza-2’-deoxycytidine in the ovarian cancer cell line 
MZ6. TUSC3 expression was below the detection limit in the mock-treated samples. 
Experiments were done in triplicates and mean values of relative TUSC3 expression 
(based on the expression of β-2-microglobulin) with standard deviations are plotted. 
E) Plots of Kaplan-Meier estimates for progression free and overall survival of 
patients with tumor samples with hypermethylated or unmethylated TUSC3. As time 
point for progression, the date of the documentation of the first relapse or the first 
documentation of the disease progression, starting at the time of the first diagnosis 
was used. P-values are from the univariate Cox regression analysis (Table 2). 
 
 
As a next step, we wanted to gain more insight into the CpG methylation 
frequency within the TUSC3 promoter region as well as to validate the results of the 
methylation specific PCR. We assessed the methylation status of individual CpG-
islands localized within the TUSC3 promoter region by bisulfite sequencing of three 
hypermethylated cell lines and two controls. The bislufite sequencing analysis 
revealed that most of the CpGs within the region of interest in the methylated cell 
lines are indeed methylated at higher frequencies (75%) than in the unmethylated 
control cell lines (10%) (data not shown). 
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3.2.4.3 TUSC3 Methylation in Primary Ovarian Tumor Samples and Correlation 
with TUSC3 Expression and Clinicopathologic Parameters 
Next, we extended the methylation analysis of the TUSC3 promoter to a panel 
of 102 primary ovarian tumor samples and 20 benign ovarian controls. Statistical 
analysis revealed no significant association of TUSC3 promoter methylation 
frequency with any clinicopathological parameters like tumor histology, grading, FIGO 
staging or age of the patients (Table 5). In this cohort, hypermethylation of the 
TUSC3 promoter was observed in 30 out of 102 (29.8%) ovarian cancer tissues but 
none of the controls (P=0.003; Fig. 8B). Consequently, mean TUSC3 mRNA 
expression in the methylated group was significantly reduced (0.065 ru) compared to 
the unmethylated group (0.135 ru, P=0.001), hinting towards methylation dependent 
gene-silencing of TUSC3 in primary ovarian tumors.  
 
Table 5. Comparision of Clinicopathologic Characteristics with Frequency of 
Hypermethylation of TUSC3 
Clinicopathologic Characteristics Hypermethylation of TUSC3 
Comparison
(P) † 
Benign ovarian samples 0 / 20 (0%)  
   
Primary Tumor Samples 30 / 102 (29.4%) 0.003 
 Age  0.218 
  ≤ 50 5 / 26 (19.2%)  
  > 50 25 / 75 (33.3%)  
 Histology  0.200 
  Serous 21 / 79 (26.6%)  
  Non-serous 9 / 22 (40.9%)  
 FIGO  0.948 
  I 5 / 17 (29.4%)  
  II 2 / 10 (20.0%)  
  III 15 / 51 (29.4%)  
  IV 7 / 22 (31.8%)  
 Grading  0.102 
  1 2 / 2 (100.0%)  
  2 15 / 48 (31.2%)  
  3 13 / 51 (25.5%)  
   
†Fisher’s Exact Test and Fisher-Freeman-Halton Test, respectively. 
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Influence of TUSC3 methylation status on progression free and overall survival 
TUSC3 promoter methylation was associated with higher rates of progressive 
disease (32.1% vs. 11.3%), prompting us to further investigate its influence on 
ovarian cancer prognosis. We found that patients with methylated TUSC3 promoter 
had significantly shorter progression free (RR 1.97, P=0.023) and overall survival 
rates (RR 2.92, P=0.007) as shown by Kaplan Meier estimates (Fig. 8E) with a 
median progression free survival of 11.1 months in the methylated group vs. 24.6 
months in the unmethylated group (Fig.8E). Cox proportional hazards analysis 
revealed a significant association between TUSC3 promoter methylation and 
progression free (RR 2.17, P=0.024) as well as overall survival (RR 4.12, P=0.008) 
which was independent from other risk factors, including response to chemotherapy, 
the strongest predictive factor in our analysis  (interaction term not significant; 
Table 6). The hazard ratio of methylated vs. unmethylated TUSC3 promoter status 
for progression free survival was significant (RR 1.97, P=0.023) and only slightly 
inferior to the increase of one FIGO stage (RR 2.82, P<0.001) or residual disease 
after surgery (RR 3.04, P=0.001). Similarly, the significant influence of TUSC3 
methylation on overall survival (RR 2.92, P=0.007) was comparable to the increase 
of one FIGO stage (RR 2.52, P=0.002), histological subtype (serous vs. non-serous 
RR 2.37, P=0.037) and  residual disease after surgery (RR 5.28, P<0.001), adding to 
the few prognostic factors available at the time when individual therapeutic options 
have to be explored.  
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Table 6. Univariate and Multiple Cox Proportional Hazards Analysis 
 Progression free survival 
 Univariate Multiple 
 Relative risk (95% CI)‡ P Relative risk (95% CI)‡ P 
Age at diagnosis 1.02 (0.99-1.05) 0.184   
Histology (non-serous v serous)† 1.16 (0.58-2.32) 0.683   
FIGO stage 2.82 (1.87-4.26) <0.001 used  
Grading 0.98 (0.58-1.65) 0.933   
Residual disease (>1cm v 
≤1cm)† 
3.04 (1.53-6.02) 0.001 used  
Therapy response (no v yes) †  4.91 (2.64-9.10) <0.001 used  
Methylation of TUSC3 (yes v 
no)† 
1.97 (1.10-3.53) 0.023 2.17 (1.11-4.24) 0.024 
 
 Overall survival 
 Univariate Multiple 
 Relative risk (95% CI)‡ P Relative risk (95% CI)‡ P 
Age at diagnosis 1.06 (1.02-1.10) 0.003 used  
Histology (non-serous v serous)† 2.37 (1.05-5.32) 0.037 used  
FIGO stage 2.52 (1.41-4.49) 0.002 used  
Grading 0.76 (0.38-1.53) 0.446   
Residual disease (>1cm v 
≤1cm)† 
5.28 (2.19-12.70) <0.001 used  
Therapy response (no v yes) †  9.56 (3.56-25.65) <0.001 used  
Methylation of TUSC3 (yes v 
no)† 
2.92 (1.35-6.29) 0.007 4.12 (1.45-11.65) 0.008 
‡CI, confidence interval. †Categorical variable. Bold, statistically significant. 
 
3.2.4.4 Generation and In-vitro Characterization of TUSC3 Cancer Cell Line 
Models 
In order to decipher the function of TUSC3, we stably reconstituted TUSC3 in 
vitro in two cancer cell lines (H134 and Mia PaCa-2), which have either low or lack 
TUSC3 expression. We transfected a full length (TUSC3) or a FLAG tagged (TFlag) 
TUSC3 mRNA-construct (Fig. 9A), resulting in a considerably altered phenotype.  
First, proliferation of TUSC3-reconstituted cells was significantly decreased 
(by 23%, corr. P=0.007 for H134 and 26%, corr. P=0.005 for Mia PaCa-2, 
respectively) compared to vector transfected controls (Fig. 9A).  
Second, transwell migration rate of the H134 ovarian cancer cell line was 
significantly enhanced by 272% (P<0.001) in TUSC3 as well as by 253% in TFlag 
transfected cell lines (P<0.001) (Fig. 9A). Interestingly, we observed incongruous 
results in the MIA PaCa-2 cell line, where migration ability was significantly inhibited 
upon TUSC3 reconstitution (-62%, P=0.001 in the TFlag transfected cell line and -
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57%, P=0.001 in the TUSC3 transfected cell line, respectively, Fig 9A). Invasiveness, 
as tested by a matrigel-transwell assay, was not significantly affected (ranging only 
from 0.1% to 1.0% for all cell lines, data not shown).  
Finally, TUSC3 reconstitution induced a change in cellular morphology of 
ovarian cancer cells, from an epitheloid-like to a rather mesenchymal phenotype. 
This phenomenon is reminiscent of the epithelial-mesenchymal transition decribed in 
several tumors and might develop secondary to a disorganized actin stress-fiber 
network (Fig. 9B). 
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Fig.9. A) In vitro characterization of cell line models with reconstituted TUSC3 
expression (H134 and MIA PaCa-2). mRNA expression is shown in arbitrary units, 
doubling time in hours and migration abilities, determined by transwell assays, in 
percent of total cell numbers. Experiments were performed in triplicates, the 
significance was calculated by the T-test and corrected for multiple testing. B) 
Morphological overview stains with phalloidin (F-actin) and DAPI (nuclei) (large 
picture) and HE stains (inset) are shown for all cell lines. C) Western blot analysis 
of subcellular fractions for FLAG-tagged TUSC3 (TUSC3-Flag) in the ovarian 
cancer cell line H134. Fractions (Ms, microsomes; Cyt, cytoplasm; Mt, 
mitochondria; Lys, lysosomes; and N, nuclei) were probed with ribophorin I, ß-actin, 
cox 5a, no marker, and nucleoporin p62, respectively. D) Colocalization experiment 
of fixed H134 cells stained for the TUSC3-FLAG fusion protein with anti-FLAG, for 
an integral endoplasmic reticulum protein with anti-calnexin, and with phalloidin as 
a counterstain. 
 
3.2.4.5 Subcellular Localization of TUSC3 
To determine the subcellular localization of TUSC3 we applied two 
independent approaches. First, western blot analysis of the FLAG tagged TUSC3 
fusion protein in highly enriched subcellular fractions of H134 cells (microsomes, 
soluble cytoplasm, mitochondria, lysosomes, and nuclei) showed its localization to 
the microsomal fraction, comprised of the endoplasmic reticulum (ER) and some 
minor amounts of cytoplasmic membranes (Fig. 9C). As a second approach, we used 
an immunofluorescent colocalization experiment, which revealed a perfect overlap of 
the TUSC3-FLAG protein and calnexin, an integral protein of the endoplasmic 
reticulum (Fig. 9D). These two methods confirm with certainty the expected 
subcellular localization of TUSC3 in the H134 cell line, namely the endoplasmatic 
reticulum. 
3.2.4.6 Functional Analysis of TUSC3 
TUSC3 might function as potential subunit of the oligosaccharyltransferase 
complex in the endoplasmic reticulum. To investigate this putative function of TUSC3 
in N-glycosylation, we performed a western blot analysis of a well known 
glycosylation target, integrin ß1, in the microsomal fractions of H134 and MIA PaCa-2 
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cells. As a control, a complete removal of N-glycosylated oligosaccharides was 
achieved by digestion with PNGase F, resulting in bands of equal mobilty at ~80 kDa, 
consistent with the calculated molecular weight of roughly 85 kDa (Fig. 10A). In both 
cell lines the ratio between mature, fully glycosylated, and incompletely glycosylated 
precursor integrin ß1 increased upon TUSC3 reconstitution (by a factor of 2.0 and 2.6 
for H134 and MIA PaCa-2, respectively; Fig. 10A). Additionally, a ~10 kDa shift 
towards higher mobility of the mature integrin ß1 was observed, suggesting a 
different N-glycosylation pattern in the reconstituted cells.  
Changes of sialylation levels of the mature integrin ß1, which cause a mobility 
shift have been described previously and might regulate its binding affinity to 
collagen I (Seales et al., 2003). Accordingly, immunohistochemical staining for 
sialylated proteins using the sambucus nigra lectin (SNA) revealed a significant 
increase in sialylation in TUSC3-positive cells compared to TUSC3-negative cells 
(Fig. 10B). 
To assess the impact of the observed glycosylation modifications of integrin 
ß1 on collagen I binding in our cell line models, we performed adhesion assays on 
collagen I-coated surfaces. Adhesion of the TUSC3 reconstituted cells to a collagen 
I-coated surface was significantly increased despite their lower levels of mature ß1 
integrin, possibly suggesting defective glycosylation or sialylation patterns (Fig. 10C). 
Hence, loss of TUSC3 might lead to decreased collagen binding and subsequent 
migration of cells in ovarian cancer, leading to their increased tumorigenicity. 
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Fig.10. A) Western blot analysis of integrin ß1 in H134 and MIA PaCa-2 cell lines. 
Integrin ß1 revealed two bands, one at ~110 kDa representing the precursor ß1-
pool in the ER, and one at ~140-150 kDa representing the mature ß1 protein. In 
TUSC3-reconstituted cell lines the band representing mature ß1 showed a ~10 
kDa shift towards higher mobility. Treatment of proteins with the deglycosylating 
enzyme, PNGase F, eliminated the differential mobility and resulted in one band 
approximately at the position of the calculated apoprotein mass (~80 kDa). 
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Adjacent to the blots, quantification curves are shown. Bands with the smaller 
values were set to unity for each cell line model. The molecular weight shift and 
the change of the mature / precursor ratio was more pronounced after a shorter 
run (inset). B) Immunocytochemical stains for integrin ß1 and sialylated poteins in 
general (SNA) are shown for the cell line models H134 and MIA PaCa-2. Cells 
were counterstained with hematoxylin/eosin. C) Adhesion of cells to 96-well 
plates coated with collagen I and BSA (as a control) were tested in octuples and 
the significance calculated by the T-test and corrected for multiple testing. Binding 
of the control cells to collagen I was arbitrarily set to unity. 
 
3.2.5 Discussion 
TUSC3, originally named N33, was originally discovered as a candidate TSG 
in the mid 1990 and is located on chromosome 8p22 within a region of frequent 
homozygous deletions. Mutational analysis performed in prostate cancer and various 
other tumor entities failed to reveal a significant rate of protein disruptive mutations 
and the interest in TUSC3 consequently vanished.  
Using publicly available gene expression profiling data, we have systematically 
screened the region on 8p22 for differentially regulated genes and identified TUSC3 
as a candidate TSG in ovarian cancer. A quantitative expression analysis confirmed 
the significant down-regulation of TUSC3 in ovarian cancer tissues and a consequent 
explorative analysis yielded significant correlations with some clinical parameters, in 
particular linking reduced TUSC3 expression at the time of diagnosis with 
unfavorable overall survival rates (Pils et al., 2005a). Similar results were recently 
obtained in head and neck tumors, where loss of N33 (TUSC3) was significantly 
correlated with poor survival (Guervos et al., 2007). In addition, the frequency of LOH 
on chromosome band 8p22 in colorectal cancer was shown to be very high (up to 
67%) and accompanied by a significantly reduced expression of TUSC3 in these 
tumors  (Andersen et al., 2007). 
In this work we validated our previous observations in a larger, completely 
independent patient population and showed for the first time and epigenetic 
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mechanism as the molecular basis of reduced TUSC3 expression in ovarian cancer 
tissues. Furthermore, we established the methylation status of the TUSC3 promoter 
as a potent independent prognostic marker for progression free and overall survival 
in ovarian cancer.The frequency of TUSC3 promoter methylation in ovarian tumor 
tissues was more than 30% compared to none in tissues derived from regular ovaries 
and from benign ovarian cysts. Methylation status significantly correlated with 
expression in tumor samples and cell lines, further establishing the epigenetic 
regulation as the main cause for low TUSC3 expression in tumors.  
Recently, the gene product of TUSC3 was acknowledged as a human 
homologue  to S. cerevisiae Ost3p shown to be associated with the 
oligosaccharyltransferase complex by copurification experiments (Kelleher et al., 
2003a). Oligosaccharyltransferase is an integral membrane protein complex in the 
ER that catalyzes N-linked glycosylation of secreted as well as membrane bound 
proteins. Whereas the loss of Ost3p in yeast results in underglycosylation of selected 
acceptor substrates in vitro (Karaoglu et al., 1995) the molecular function of TUSC3 
in the human oligosaccharyltransferase protein complex remained unclear  (Kelleher 
et al., 2003a). Aberrant glycosylation of proteins can be found in essentially all in vitro 
cancer models and human cancers, and many glycosylated epitopes constitute 
tumor-associated antigens (Hakomori, 2002; Kobata and Amano, 2005) causing a 
long-standing debate whether aberrant glycosylation is a result or a cause of cancer. 
Our functional analysis adds some small, but crucial data to the incremental 
understanding of the causal connexion between TUSC3, glycosylation and cancer.  
We were able to show the subcellular localization of TUSC3 to the ER, as predicted 
from its homology to OSTP3p, by using FLAG-tagged fusion constructs. In both cell 
line models high TUSC3 expression correlated significantly with decreased 
proliferation. This fact is consistent with the role of TUSC3 as a TSG. Poor prognosis 
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of patients with TUSC3 negative (promoter methylated) cancers might be partly 
dependent on the increased proliferation of cancer cells as shown by our in vitro 
data. The inter-cell line phenotypic variability of the migration and invasion properties 
observed in our experiments, might be explained by the differences in the tissue of 
origin (ovary vs. pancreas) of the individual cancer cell lines. This observation is not 
surprising, judged by the highly variable and tissue dependent TUSC3 expression 
levels in whole genome expression profiles (data not shown).  
The glycosylation pattern of the mature integrin ß1 protein and the ratio of 
mature to precursor protein changed uniformly upon TUSC3 reexpression in two 
carcinoma cell lines of different origins (ovary and pancreas). Furthermore, the 
amount of sialylated glycoproteins was substantially decreased in both TUSC3-
negative cell lines. Therefore, we conclude that TUSC3 is involved in the post-
translational maturation (i.e. glycosylation) of integrin ß1 and probably other 
glycoproteins. Integrin ß1 signalling is regulated by extracellular matrix (ECM) 
binding, affecting multiple cellular functions such as proliferation, changes in 
cytoskeletal organization and motility, Modifications of integrin ß1 glycosylation are a 
well confirmed regulatory mechanism for ECM binding and subsequent signalling  
(Seales et al., 2003). Local tumor dissemination to the peritoneum (transcoelomic 
metastasis) is the predominant mechanism of tumor progression in ovarian cancer 
and the main reason for the poor prognosis of this disease. The current hypothesis 
proposes tumor cell aggregates, so-called spheroids, rather than single cells may be 
responsible for this dissemination. Collagen I is a major component of the peritoneal 
mesothelium and promotes integrin ß1-mediated spheroid adhesion and 
dissemination (Burleson et al., 2006; Burleson et al., 2004a; Burleson et al., 2004b; 
Lessan et al., 1999). Therefore, the significantly increased affinity of TUSC3-negative 
cells to collagen I, caused by differential integrin ß1 glycosylation, provides an 
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intriguingly plain explanation for the strong tumor suppressive function of TUSC3, 
cumulating in a prominent impact on patient outcome (as shown in univariate and 
multiple cox regression analyses). Furthermore, changes of integrin ß1 glycosylation 
were shown to affect cell migration by cytoskeletal rearrangements as indicated by a 
disorganized actin stress-fiber network (Guo et al., 2002), which we also observed in 
our cell line models. 
Regardless of the detailed molecular function of TUSC3, TUSC3 promoter 
methylation is a promising new prognostic marker for ovarian cancer, which deserves 
to be evaluated prospectively. Given the poor prognosis, the availability of DNA 
demethylating agents and inhibitors histone deacetylases (e.g. decitabine and 
zebularin) (Momparler, 2005) and the superior response to intraperitoneally 
administered chemotherapy compared to systemic chemotherapy (Armstrong et al., 
2006), patients with hypermethylated TUSC3 genes may profit from the combination 
of epigenetic modifiers with conventional chemotherapy. An even more specific 
approach could be an antagonistic therapy targeting integrin ß1, especially in 
patients with TUSC3 promoter methylation. A deeper understanding of the role of 
TUSC3 in protein glycosylation may offer additional possibilities for therapeutic 
interventions in the future. 
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4 Concluding Remarks and Future Directions 
 
The short arm of chromosome 8 is frequently altered in human cancer. 8p22 is 
a particular deletion hot spot suggesting the presence of tumor suppressor genes 
(TSG) in this area. The most accurately characterized TSG in this region is DLC1, a 
Rho GTPase-activating protein, which identified by a deletion mapping approach. 
Originally, it has been characterized in hepatocellular carcinoma, but most likely 
plays a role in several cancer types (Durkin et al., 2007; Xue et al., 2008). Using 
publicly available gene expression profiling data, we have systematically screened 
the region on 8p22 for differentially regulated genes and identified hVps37A and 
TUSC3 as candidate TSGs in ovarian cancer. Quantitative expression analysis 
confirmed the significant down-regulation of hVps37A and TUSC3 in ovarian cancer 
tissues and a consequent explorative analysis yielded significant correlations with 
some clinical parameters. In particular, we could link reduced hVps37A and TUSC3 
mRNA expression in tumors to unfavorable overall survival rates (Pils et al., 2005b). 
In this work our previous results were validated in a larger, completely 
independent patient population. Subsequently, hVps37A and TUSC3 were 
characterized in more depth with respect to their molecular function and 
corresponding clinical implications. hVps37A prooved to be essential for the 
degradation process of EGFR and HER2 and determined their prognostic 
significance for overall survival in ovarian cancer. Moreover, low hVps37A expression 
confered resistance against the EGFR antagonistic antibody Cetuximab in vitro.  
The promoter region of TUSC3 was found to be frequently methylated in 
ovarian tumor samples, associated with reduced mRNA expression and unfavorable 
survival rates. Furthermore, we identified TUSC3 to localize to the endoplasmatic 
reticulum and to function in N-glycosylation of integrin-ß1 and potentially several 
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other proteins. Overall, we describe two molecular markers, which determine patient 
survival and response to targeted therapies. Since only few molecular markers are 
available for ovarian cancer, clinical utilization of TUSC3 or hVps37A would 
potentially lead to advances in ovarian cancer diagnosis and treatment. 
In order to reach a final conclusion about their clinical value, more experiments 
will have to be conducted. As mentioned above, hVps37A knock-down in ovarian 
cancer cell lines introduced a resistance mechanism against the monoclonal antibody 
Cetuximab, caused by ineffective EGFR degradation. Ongoing studies of our group 
aim to determine clinical impact of hVps37A expression on response of Non Small 
Cell Lung Cancer (NSCLC) patients to Cetuximab therapy. In case a significant 
correlation can be observed and reproduced in other EGFR overexpressing cancer 
entities, we will establish hVps37A as molecular marker for Cetuximab based therapy 
in clinical practice. A patent describing a procedure to predict Cetuximab response 
rates based on hVps37A expression was recently submitted by our group. 
In order to shed more light on hVps37A function, we recently established a 
mouse xenograft model applying the above described SKOV-3 Tet-Off cell line. 
Preliminary results indicate, that tumor growth in mice is elevated upon hVps37A 
knock-down. TUNEL assays as well as Ki-67 assays of the corresponding tumors will 
show if enhanced tumor growth is a result of elevated proliferation of reduced 
apoptosis rates. A 3D cell culture experiment showed that hVps37A-silenced cells 
gained the ability to invatde a collagen matrix more efficiently. In line with current 
literature (Arora et al., 2008; Yang et al., 2004), this finding may be traced back to 
dysregulated EGFR-downstream pathways (Figure 7A, B). Overall, we have 
promising upcoming results which will be validated over the next months. 
We will also further investigate cellular function and clinical impact of TUSC3. 
IHC on tissue microarrays containing primary ovarian tumor samples should confirm 
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the negative impact of low TUSC3 expression obtained by RNA-expression analysis. 
The knowledge of TUSC3 cellular localization is a prerequisite for the understanding 
of its function. According to a recently published study, TUSC3 is weakly associated 
to the oligosaccharyltransferase complex in the endoplasmatic reticulum (Kelleher et 
al., 2003b). We plan dual-immunofluorescence staining experiments of fixed cancer 
cells using several cell-compartment markers in addition to antibodies directed 
against TUSC3 or a C-terminal TUSC3 tag in order to prove and substantiate our 
previous findings. Furthermore, in-vivo experiments using mouse xenografts of 
overexpressing and silenced TUSC3 cell lines will be performed to evaluate the 
potential influence of TUSC3 expression on tumor growth. The expected attenuation 
of tumor formation mediated by TUSC3 will be examined by immunohistochemistry 
and TUNEL assays on histological sections.  
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6.1 Abstract 
TGF-ß signalling via Smads plays a central role in carcinogenesis. BAMBI was 
initially described as pseudoreceptor antagonizing TGF-ß receptor activation thus 
impairing signalling. We demonstrate for the first time a nuclear cotranslocation of 
BAMBI with Smad2/3 upon TGF-ß treatment employing intracellular localisation 
experiments. 
Overexpression of BAMBI led to increased proliferation, migration, and resistance to 
TGF-ß-mediated apoptosis. Although – prima facie – this fits to the thesis of BAMBI 
as pseudoreceptor, it could also be explained by modulation of TGF-ß signalling in 
the nucleus, leading to the observed pro-oncogenic properties. The tumor promoting 
impact of BAMBI mRNA expression in vitro could not be confirmed in primary tumor 
samples. Whereas nearly all tumor samples showed up-regulation of BAMBI 
compared to undetectable BAMBI in healthy ovarian epithelia no impact of BAMBI 
expression on overall survival could be observed. These findings suggest a more 
complex view of Smad-mediated transcription regulation, including BAMBI as novel 
modulator. 
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6.2 Introduction 
Epithelial ovarian cancer is the most lethal gynecologic malignancy and with about 
six percent the fourth most frequent cause of cancer-related death of women in 
western countries. Estimates indicate that one of 70 women will develop ovarian 
cancer in her lifetime with a median survival rate of approximately 4.5 years. Recent 
cancer statistics estimated 22,430 new cases and 15,280 deaths per year in the 
United States (Jemal et al. 2007).  
Loss of accurate response to growth inhibiting signals, such as transforming growth 
factor (TGF)-ß occurs frequently during cancerogenesis. TGF-ß affects various 
cellular processes including regulation of differentiation, migration, apoptosis, and 
proliferation of epithelial cells (Massague et al. 2000b; Bierie and Moses 2006c). The 
three TGF-ß isoforms (TGF-ß1, TGF-ß2 and TGF-ß3) recognize type I, II, and III 
TGF receptors (TGF-ßRI, TGF-ßRII and betaglycan or endoglin, respectively) to 
initiate signalling via the activation of transcriptional co-regulators named Smads 
(Bierie and Moses 2006b). In detail, activation of the TGF-ßRI triggers Smad2 and 
Smad3 phosphorylation which subsequently translocate from the cytoplasm to the 
nucleus as a complex with Smad4. Interacting with specific DNA binding sites they 
induce or repress the transcription of corresponding target genes (Miyazono et al. 
2000).  
The functional TGF-ßRII/TGF-ßRI heteromeric signalling complex is is described as 
tumor promoter acting via SMAD-dependent but also alternative pathways(Siegel and 
Massague 2003; Derynck and Zhang 2003; Moustakas and Heldin 2005; Barrios-
Rodiles et al. 2005). Smad-independent TGF-regulated networks include signalling 
mocules like RHOA, cell division cycle 42 (CDC42), RAC1, Ras, phosphatidylinositol 
3-kinase (PI3K), protein phosphatase 2A (PP2A), mitogen-activated protein kinase 
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kinase kinase 1 (MAP3K1, also known as MEKK1), TGF-activated kinase 1 (TAK1) 
(Bierie and Moses 2006a).  
Resistance against antiproliferative effects of TGF-ß signalling contributes to the 
development of many epithelial cancers (Massague et al. 2000a; Gotzmann et al. 
2004), including ovarian cancer (Yamada et al. 1999; Baldwin et al. 2003; Nilsson 
and Skinner 2002; Rodriguez et al. 2001). Although accumulating knowledge 
concerning TGF-ß resistance is available, the mechanisms are poorly understood in 
ovarian cancer. Recently, Sunde et al. found a number of genes involved in TGF-ß 
signalling which are differentially expressed in ovarian cancer specimens compared 
to normal ovarian surface epithelium. In particular, genes that inhibit TGF-ß signalling 
were up-regulated in advanced-stage ovarian cancers while genes that enhance 
TGF-ß signalling were down-regulated (Sunde et al. 2006). 
The pseudoreceptor BAMBI (BMP and activin membrane-bound inhibitor), formerly 
also called NMA, is known inhibitor of the TGF-ß signalling pathway (Sekiya et al. 
2004a; Onichtchouk et al. 1999d; Degen et al. 1996; Sekiya et al. 2004d). BAMBI 
exhibits structural homology to TGF-ßRI but lacks an intracellular kinase domain 
(Onichtchouk et al. 1999c).  
Expression of BAMBI has been shown to be aberrantly elevated in most colorectal 
and hepatocellular carcinomas, caused by ß-catenin signalling (Sekiya et al. 2004b). 
In HepG2 hepatoma cells, transcription of BAMBI is regulated via a feedback loop 
which confers binding of Smad3 and Smad4 to the Smad-responsive elements of the 
BAMBI promoter (Sekiya et al. 2004c). 
The significance of TGF-ß signalling raised the question of the function of BAMBI in 
ovarian cancer. Thus, we characterised the role of BAMBI in an ovarian cancer cell 
line and evaluated the impact of BAMBI expression on ovarian cancer patients 
outcome. 
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6.3 Results  
6.3.1 Generation and Analysis of BAMBI Overexpressing SKOV3 Cells  
We employed the ovarian cancer cell line SKOV3 because of its low endogenous 
BAMBI expression. For overexpression of BAMBI the full length ORF of BAMBI was 
cloned into the pLP-IRESneo vector. This construct or the empty vector as control 
were stably transfected into SKOV3 cells and BAMBI expression was determined. On 
the mRNA level the SKOV3 BAMBI clone showed a 35.5-fold overexpression 
compared to the SKOV3 control cell line (Co) (Fig. 1A) which resulted in a clearly 
visible BAMBI band on Western blots (Fig. 1B). BAMBI overexpression significantly 
enhanced cellular proliferation (doubling time -37.0%, P=0.010; Fig. 1C) as well as 
increased migration capability in trans-well migration assays (+581.2%, P=0.004) 
compared to the control (Fig. 1D). Interestingly, altered migration was not associated 
with a morphologic phenotype as shown by HE and phalloidin staining for F-actin 
(Fig. 1G) The relatively low invasiveness of the SKOV3 cell line in matrigel invasion 
assays was not essentially affected by BAMBI overexpression (Fig. 1E). 
Supplementation with 2.5 ng ml-1 TGF-ß resulted in a 7.6% inhibition of proliferation 
in the control cells, whereas SKOV3 BAMBI cells were not affected (Fig. 1F). 
Apoptosis as detected by FACS analysis with Annexin V-FITC decreased from 30% 
in the SKOV3 Co cells to 7% in the SKOV3 BAMBI cells upon induction by TGF-ß 
(data not shown). In another cell line with low endogenous BAMBI expression, MDAH 
2774, proliferation decreased significantly (26.7%, P=0.005) upon TGF-ß 
supplementation, consistent with enhanced TGF-ß sensitivity (9.8% and 19.0% 
apoptosis in the absence and presence of TGF-ß, respectively, corresponding to an 
increase of +93.9%) (data not shown). 
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Figure 1 In vitro characterization of the BAMBI-overexpressing SKOV3 cells. 
Relative BAMBI mRNA (A) and BAMBI protein levels (B) were higher in SKOV3 
BAMBI cells as compared to SKOV3 control (Co) cells. Upon BAMBI 
overexpression proliferation (C) as well as migration rates (D) increased 
significantly, whereas increase in invasion was not significant (E). Sensitivity to 
growth inhibition by TGF-ß was reduced in the SKOV3 BAMBI cells compared to 
SKOV3 Co cells (F). Stain for whole cell morphology (hematoxylin and eosin, HE) 
and for F-actin (phalloidin with DAPI as counterstain) (G). Data are given in mean 
and standard deviations of triplicate experiments. 
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6.3.2 TGF-ß Signalling in Ovarian Cancer Cell Lines and Intracellular 
Localization of BAMBI 
Canonical TGF-ß signalling leads to phosphorylation of Smad2 and Smad3 proteins, 
which translocate together with Smad4 into the nucleus. The impact of BAMBI 
overexpression on this process was investigated by immunocytochemical staining of 
BAMBI and Smad2/3 proteins. As expected, Smads translocate into the nucleus 
upon stimulation of the cells with TGF-ß for 10 minutes, exhibiting decreased 
cytoplasmic and increased nuclear staining intensities. Interestingly, elevated nuclear 
staining of BAMBI in TGF-ß-treated cells indicates a cotranslocation with Smads (Fig. 
2). Since BAMBI was described as pseudoreceptor with a transmembrane region 
directly binding to TGF-ß (Onichtchouk et al. 1999b) this result was highly 
unexpected.  
 
 Figure 2 Regulation of BAMBI 
mRNA expression by TGF-ß in 
MDAH 2774 clones. MDAH clones 
with initially low (MDAH Co) or high 
(MDAH BAMBI) BAMBI expression 
levels were grown in triplicates in 
the presence of different 
concentrations of TGF-ß, resulting 
in a concentration-dependent and 
significant upregulation of BAMBI 
transcripts. 
 
 
 
 
 
 
 
 
 
 
 
In order to verify this this observation and eleminating localization artefacts from 
BAMBI overexpression in the SKOV3 BAMBI clone, this experiment was confirmed 
by immunofluorescent colocalization experiments on another ovarian cancer cell line 
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with substantial endogenous BAMBI expression, namely H134. Again, cytoplasmic 
BAMBI as well as Smad2/3 diminished and accumulated in the nucleus upon TGF-ß 
treatment (Fig. 3A), corroborating the finding of BAMBI and Smad cotranslocation in 
the SKOV3 BAMBI cells. Consistent with the translocation of Smads into the nucleus, 
staining of phosphorylated Smad2 (p-Smad2) exhibited high p-Smad2 levels in the 
nucleus upon TGF-ß treatment whereas staining was nearly undetectable in 
untreated cells (Fig. 3A), indicating traditional TGF-ß signalling including 
phosphorylation of the Smads.  
Since unspecific nuclear staining by fluorescent conjugates could provide artefacts, 
localisation of BAMBI was further analyzed by immunoblotting of subcellular 
fractions. 
Therefore, purified fractions of the nuclei, the microsomes (with a minor contribution 
of cytoplasmic membranes), and the soluble cytoplasm were prepared from the H134 
and MDAH 2774 cell lines (to avoid over-expresion artefacts not from SKVO3 
BAMBI). Western blots were probed for nucleoporin p61 as a nuclear marker and ß-
actin as a cytoplasmic marker as fraction quality controls. 
Upon TGF-ß stimulation, Smad2 and Smad3 translocate to the nucleus together with 
BAMBI in a nearly stoichiometrical ratio in both cell lines (Fig. 3B), substantiating our 
immunocytochemical and immunofluorescence staining experiments.  
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Figure 3 Smad2/3-BAMBI-cotranslocation in H134 and MDAH 2774 clones. 
Immunofluorescence staining for Smad2/3 and BAMBI in H134 cells revealed a 
shift of fluorescence from the cytoplasm to the nucleus upon treatment with TGF-ß 
(counterstained with DAPI) (A). Western blot analysis of subcellular fractions of 
both MDAH 2774 clones and H134 cells (B). The quantity of subcellular fractions 
was evaluated by staining with the nuclear and cytoplasmic markers nucleoporin 
p61 and ß-actin, respectively. Smad2/3 and BAMBI levels in the nuclear fraction 
increased significantly upon treatment of the cells with TGF-ß, for both MDAH 2774 
clones even in a nearly stoichiometric ratio. (Band intensities before TGF-ß 
treatment were set to unity and the calculation was performed on a longer-exposed 
film after normalization to the nucleoporin band intensities. In the H134 cells we 
could not detect BAMBI in the nucleus before incubation with TGF-ß, therefore no 
calculation was possible). 
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6.3.3 BAMBI mRNA Expression in 69 Ovarian Cancer Samples and 
Correlation with Clinicopathologic Parameters 
Next we addressed the question if BAMBI expression has the potential to influence 
survival rates of ovarian cancer patients. Therefore we quantified the BAMBI mRNA 
of 69 ovarian cancer patients relative to ß-2-microglobulin by RT-qPCR. 
Clinicopathologic characteristics of the patients are shown in Table 2. The tumor 
samples represent a typical distribution of ovarian cancer patients frequenting a 
university hospital. In particular, 74% of tumors were of serous type and 68% of 
patients displayed an advanced stage of tumor progression (FIGO III and IV). The 
mean follow up time was 20.6 months with 25% of cases of death. We observed no 
significant BAMBI mRNA expression variations between any groups of histological 
type, FIGO stage, Grade, or in patients without recurrences compared to patients 
with recurrences or progressive disease (Table 2). Kaplan-Meier estimation showed 
no difference in overall survival if samples were divided into three groups at the 33.3 
and 66.6 percentile (Fig. 5), nor after dichotomisation at the. median, 25% or 75% 
percentiles, respectively. On the other hand, the FIGO stage – one of the strongest 
predictive clinical parameters – showed a clear significant impact on overall survival 
according to Kaplan-Meier estimates (Fig. 5). Multivariate analysis using different or 
all of the clinicopathologic parameters as given in Table 2 together with BAMBI 
expression never revealed a significant impact of BAMBI expression on overall 
survival (data not shown). 
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Figure 5 Impact of mRNA and protein levels of BAMBI on patient outcome. BAMBI 
mRNA or protein levels were obtained from independent patient cohorts by qRT-
PCR or immunohistochemistry, respectively. As expected, FIGO stages had 
significant impact on patient overall survival in both patient cohorts, but neither 
mRNA expression levels (divided into three categories according to the 33.3 and 
66.6 percentile) nor protein levels (dichotomized into two groups, 0/1+ compared to 
2+/3+, see Fig. 5) had negative impact on overall survival. 
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Ovarian tumor samples (qRT-PCR) 69 Mean (±SD) 
Age at diagnosis [mean in years (range)] 57.9 (36 – 86)  
 Follow-up [mean in months (range)] 20.6 (0.0 – 46.0) P = 0.757a 
 Alive 52 (75.4%) 0.168 (±0.927) 
 Dead 17 (24.6%) 0.020 (±0.032) 
Histology  P = 0.520b 
 Serous 51 0.0361 (±0.098) 
 Endometrioid 7 0.0544 (±0.102) 
 Mucinous 4 1.689 (±3.328) 
 Clear cell 2 0.010 (±0.009) 
 other (e.g. mixed) 5 0.013 (±0.018) 
FIGO  P = 0.819b 
 I 15 0.063 (±0.161) 
 II 7 0.064 (±0.105) 
 III 31 0.239 (±1.197) 
 IV 16 0.016 (±0.021) 
Grade  P = 0.642b 
 1 1 0.006 
 2 34 0.230 (±1.142) 
 3 34 0.131 (±0.805) 
Recurrences (1 missing)  P = 0.378a 
 w/o recurrence 35 0.240 (±1.127) 
 w/ recurrence 22 0.014 (±0.017) 
 Progressive disease 11 0.028 (±0.038) 
 
Table 2 mRNA expression of BAMBI and correlation with clinicopathologic 
characteristics of 69 primary ovarian tumor tissues.  
 
6.3.4 BAMBI Protein Expression in Four Normal and 51 Ovarian Tumor 
Tissues and Correlation with Clinicopathologic Parameters 
To assess the impact of BAMBI on patient outcome on the more disease-relevant 
protein level, we performed immunohistochemical staining of 51 paraffin-embedded 
ovarian tumor tissues, which did not overlap with the pattient cohort of the mRNA 
expression study. In addition, four paraffin-embedded normal ovaries (two pre-
menopausal and two post-menopausal) were used as references. Distribution of 
clinicopathologic characteristics was representative for ovarian cancer patients 
frequenting an university hospital, namely 63% had a serous type cancer histology 
and 65% were in late stages (FIGO III and IV). The mean follow-up time was 60.6 
months with 16 cases of death (31.4%). BAMBI localized to the cytoplasmic and 
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nuclear cellular compartment and was uniformly distributed within the tumor. 
Consequently, we classified the staining of tumor tissues solely according to staining 
intensity into 4 groups (‘0’ virtually no staining, ‘1+’ weak staining, ‘2+’ intermediate 
staining, and ‘3+’ strong staining) (Fig. 4). Whereas BAMBI was undetectable in all of 
the controls, we observed a positive staining in 48 out of 51 tumor tissues, indicating 
that BAMBI overexpression in ovarian cancer is a relatively common event. 
Frequencies of staining intensities are outlined in Table 3. However, we detected no 
differential staining intensities between tumors of different histologies, different FIGO 
stages, or different Grades. Equally BAMBI mRNA expression, protein staining 
intensities did not influence overall survival rates in univariate or multivariate analysis 
when patients were dichotomized in 0/1+ and 2+/3+ staining intensities (Fig. 5). The 
only significant predictor of overvall survival was again FIGO stage (Fig. 5).  
 
Figure 4  
Immunohistochemical staining of 
BAMBI in normal and malignant 
ovarian tissues. Pre-menopausal (A) 
and post-menopausal (B) ovarian 
surface epithelial cells (arrows) 
displayed no detectable BAMBI levels. 
BAMBI staining intensities of malignant 
ovarian tumor tissues were uniform 
and therefore classified solely 
according to their staining intensities 
into four groups (0, 1+, 2+, and 3+) 
(C). 
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6.4 Discussion 
During the course of carcinogenesis TGF-ß signalling is frequently altered to 
overcome its antiproliferative effect. Six serin/threonine kinase receptors (TßRI-III, 
ActR-IB, BMPR-IA/IB) are known to mediate TGF-ß signalling which is involved in 
diverse cellular functions. BAMBI has been described as a protein with weak 
homology to TGF-ß receptors, containing a membrane domain but no active kinase 
domain. Co-immunoprecipitation experiments revealed interactions between BAMBI 
and most of the TGF-ß receptors leading to inhibition of functional TGF-ß type I- and 
type II-complex formation, thus impairing downstream signalling events, as shown by 
several reporter gene assays (Onichtchouk et al. 1999a).  
Upon BAMBI overexpression in the ovarian cancer cell line SKOV3 all examined in 
vitro physiological parameters point to enhanced oncogenic characteristics: 
significantly increased proliferation, migration, (invasion, albeit not significant), and 
decreased sensitivity to TGF-ß-mediated growth inhibition.  
Translocation of phosphorylated Smad2/3 into the nucleus upon activation of TGF-ß 
receptors provides a simple and direct model for investigation of BAMBI function as 
an inhibiting pseudoreceptor. Therefore we performed immunostained BAMBI, 
Smad2/3, and p-Smad2 in TGF-ß-treated cells (Figs 2 and 3A). Surprisingly, TGF-ß-
mediated Smad2/3 translocation and Smad2 phosphorylation was not impaired by 
BAMBI (over)expression (Fig. 2 and 3). Even more unexpectedly, increased amounts 
of BAMBI were observed in TGF-ß-treated cells by immunocytochemical as well as 
immunofluorescenc staining experiments (Fig. 2, 3A), together indicating a co-
translocation of Smads and BAMBI into the nucleus. In order to verify this novel 
finding and to get some quantitative information about the putative TGF-ß-induced 
Smad-BAMBI co-translocation, we performed Western blotting analysis of subcellular 
fractions. As demonstrated in Fig. 3B, Smad2/3 accumulated in the nuclear fraction 
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together with a nearly proportional amount of BAMBI upon TGF-ß treatment, proving 
the model of Smad-BAMBI co-translocation in ovarian cancer cells. 
Although we could show that BAMBI is involved in TGF-ß signalling, we propose that 
BAMBI modulates rather than inhibits TGF-ß signalling. This conclusion is further 
supported by the very weak homology between TGF-ß superfamily receptors and 
BAMBI. Amino acid identities vary between 6.1 (to BmprIA) and 9.1 (to BmprIB) 
percent. Values above 10% are commonly considered to allow functional predictions 
of homologous proteins. Other pseudoreceptor systems show significant higher 
homologies (e.g. TRAIL receptors DR4 and DR5 compared to their pseudoreceptors 
DcR1 and DcR2 showed amino acid identities between 21.9% and 45.9%). 
Intriguingly, the only BAMBI interaction partner found by protein-protein interaction 
screenings so far was SOX30, a known transcription factor containing a HMG box 
DNA-binding domain (Rual et al. 2005).  
Since the in vitro characterization of the BAMBI overexpression models suggest a 
pro-oncogenic effect, we evaluated the impact of BAMBI expression on ovarian 
cancer patient outcome. BAMBI mRNA and protein levels were assessed using 
quantitative real time RT-PCR and immunohistochemistry staining of ovarian tumor 
and normal ovarian tissues. Human ovarian epithelial cells (HOSE) from two pre-
menopausal and two post-menopausal ovarian sections showed no staining (Fig. 4A 
and B), indicating that BAMBI expression is not detectable in HOSE cells. However, 
BAMBI expression was detectable in 94% of 51 tumor samples (Fig. 4C), showing 
that BAMBI overexpression is a common event in ovarian cancerogenesis. Staining 
intensities – classified in four groups – did not correlate with any clinicopathologic 
parameters (Table 3). Despite the frequent event of BAMBI mRNA and protein 
overexpression in ovarian tumors and indications for oncogenic activities in vitro, 
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BAMBI staining intensities had no impact on overall survival of patients (Fig. 5, 
Table 2).  
As conclusion, BAMBI – initially described as a pseudoreceptor, inhibiting TGF-ß 
superfamiliy signalling – a) cotranslocates together with Smads into the nucleus upon 
TGF-ß treatment of the cells, b) modulates rather than inhibits TGF-ß signalling, c) is 
overexpressed in nearly all ovarian cancer tissues, d) rendering a new non-
prognostic tumor marker without impact on patient outcome.  
The very weak homology of BAMBI to its corresponding receptors, the absent 
overlap of TGF-ß and BAMBI regulated genes, and the nuclear localisation of BAMBI 
upon TGF-ß treatment raises the interesting question whether BAMBI functions as a 
novel modulator of Smad-mediated transcriptional regulation which warrants further 
investigations. 
 
6.5 Materials and Methods 
6.5.1 Cell lines, BAMBI Cloning, and Transfection of SKOV3 
The human ovarian carcinoma cell lines MDAH 2774 was cultured in RPMI medium 
with 10% FCS (fetal calf serum), 50 units ml-1 penicillin G, and 50 µg ml-1 
streptomycin sulfate at 37°C in a humidified atmosphere of 95% air with 5% CO2. 
SKOV3, SKOV3 Co, and SKOV3 BAMBI cells were cultured in McCoy’s medium 
supplemented with 10% FCS, 50 units ml-1 penicillin G, and 50 µg ml-1 streptomycin 
sulfate. Selection of stable transfectants was archieved by growth in the presence of 
200 µg ml-1 G418 and subculturing with 100 µg ml-1 G418. Growth with TGF-ß was 
performed in growth medium supplemented with 1 or 2.5 ng ml-1 TGF-ß for at least 
one week with medium change every second day. For BAMBI overexpression, the 
full length ORF of BAMBI (acc. no. BC019252) was cloned from the vector pOTB7 
(Sma I, Xho I) into the pLP-IRES neo vector (Eco RV). This construct and pLP-
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IRESneo as a control were transfected into SKOV3 cells using Lipofectamine 2000 
(Invitrogen, Carlsbad, CA, USA). Stable clones were selected, picked and 
subcultured. 
6.5.2 Patient Material 
For mRNA expression analysis, ovarian tumor samples from primary tumors and 
corresponding clinicopathologic parameters were obtained from 69 patients who 
underwent optimal debulking surgery at the Charité hospital in Berlin, Germany. For 
immunohistochemical studies on paraffin-embedded tissues, 51 ovarian tumor 
samples were obtained from ovarian tumor patients at primary diagnosis who 
underwent optimal debulking surgery, and four normal ovaries were obtained from 
patients without malignant disease, both surgically removed at the Medical University 
of Vienna (AKH). Relevant clinical information was collected, and tissue samples and 
clinical data anonymized. Informed consent for the scientific use of biological material 
was obtained from all patients in accordance to the requirements of the ethics 
committee of the institutions involved. 
6.5.3 Phenotypical Characterization of Cell Lines 
Expression of BAMBI was measured by quantitative real time RT-PCR essentially as 
described previously (Pils et al. 2005) using the TaqMan® Gene Expression Assays 
Hs00180818_m1 for BAMBI, and Hs99999909_m1 for HPRT1 or Hs99999907_m1 
for beta-2-microglobulin as house-keeping controls (Applied Biosystems, Foster City, 
CA, USA). Expression is given in arbitrary units. For the BAMBI Western blot 
analysis, 30 µg of total protein prepared with RIPA+-buffer was separated by 12% 
SDS-PAGE and blotted on PVDF membranes. The antibodies used were: 
monoclonal mouse anti-BAMBI (Abnova corp., Taipei, Taiwan) in a 1:400 dilution, 
polyclonal goat anti-mouse HRP-conjugate (Calbiochem, Darmstadt, Germany) in a 
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1:10,000 dilution, and rabbit anti-actin HRP-conjugate (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) in a 1:500 dilution.   
Proliferation (doubling time) was measured in triplicates by subsequent cultivation 
and cell counting by CASY cell counter (Innovatis AG, Bielefeld, Germany). Doubling 
time (td) was calculated as follows: µ=(ln(xt)-ln(x0))/t, td= ln(2)/µ (xt, cell number at 
time t; x0, cell number at start of experiment; t, duration of experiment). 
Migration and invasion assays were performed in a 24-well plate trans-well system 
(BD Biosciences, San Jose, CA, USA). For migration and invasion assays, 2.5 104 
cells were seeded in triplicates on the 8.0 µm pore size control chambers for 
migration and the BD Matrigel invasion chambers (pore size: 8.0 µm) for invasion. 
30% FCS was used as chemoattractant. After 24 h incubation cells from both sides of 
the membrane were trypsinised, harvested and reseeded in 96-well plates in 
appropriate densities. After 4 h of cell-settlement, cell numbers were estimated by the 
Cell Titer-Blue® cell viability assay, based on conversion of resazurin to fluorescent 
resorufin (Promega, Madison, WI, USA). Results were given in percent calculated as 
follows: after subtraction of blank values, the fluorescence (560Ex/595Em nm) in cells 
from the lower side of the membrane (corresponding to the migrated/invaded cells) 
was divided by the sum of fluorescence values in cells from both sides of the filter 
(corresponding to all seeded cells) and multiplied with 100. 
6.5.4 Immunocytochemical and Immunohistochemical Staining 
For immunocytochemical staining cells were grown overnight on sterile four-well Lab-
Tek™ Chamber Slides™ (Nagle Nunc International, Rochester, NY, USA). After 
washing with PBS, cells were fixed in 3% formaldehyde/PBS for 20 minutes at room 
temperature and permeabilized with 0.5% Triton X-100/PBS for five minutes. 
Endogenous peroxidase activity was blocked by a ten minute incubation with 3% 
H2O2/PBS. Subsequently, cells were blocked for 30 minutes with 0.2% fish 
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gelatine/PBS and incubated with the primary antibody diluted in 0.2% fish 
gelatine/PBS for 60 minutes at room temperature. Dilutions in 0.2% fish gelatine/PBS 
of primary antibodies were as follows: anti-BAMBI, 1:200; anti-Smad2/3 (BD 
Biosciences, San Jose, CA, USA), 1:100. After washing with PBS, biotin-conjugated 
secondary antibody goat-anti mouse, 1:200 in 0.2% fish-gelatine/PBS (BA9200, 
Vector Laboratories, Burlingame, CA, USA) was applied for 30 minutes followed by 
incubation with the streptavidin ABComplex-HRP (ABC-Kit from Dako, Glostrup, 
Denmark) for 45 minutes and  subsequent DAB+ (Dako) staining performed 
according to the manufacturer’s instruction. Finally cells were stained with 
hematoxyline/eosin and mounted in Eukitt (O. Kindler GmbH, Freiburg, Germany). 
Microscopy was performed on an Olympus BX50 upright light microscope (Olympus 
Europe, Hamburg, Germany) equipped with the Soft Imaging system CC12. 
For immunohistochemical staining (Pils et al. 2007), 5 µm paraffin sections of the 
paraffin-embedded tissues were deparaffinized with xylenes and rehydrated by 
incubation in serial dilutions of ethanol. Subsequently, antigen retrieval was 
performed based on a citrate buffer protocol (incubation in 1:20 diluted citrate buffer 
(pH 9) DEPP-9 (Eubio, Vienna, Austria) at 96°C for 20 minutes). Sections were 
treated with 3% H2O2/PBS (pH 7.4) to quench endogenous peroxidases and blocked 
with 10% normal goat serum for 30 min. Afterwards the sections were incubated with 
monoclonal mouse anti-BAMBI antibody at a 1:200 dilution in 10% serum at RT for 
60 minutes. After washing with PBS, biotin-conjugated goat anti-mouse antibody 
(BA9200, Dako, Carpinteria, CA, USA) was applied at a 1:200 dilution in 10% 
serum/PBS for 30 minutes, followed by washing and incubation with the streptavidin 
ABComplex-HRP (ABC-Kit, Dako) for 45 minutes. Finally DAB+ (Dako) staining was 
performed for 10 minutes according to the manufacturer’s instruction. Meyer’s 
Side Project   90
hematoxyline was used for counterstaining the nuclei. Staining intensities were rated 
by two individual physicians under the supervision of a pathologist. 
6.5.5 Immunofluorescence Staining 
Cells were grown overnight on sterile polystyrene slides (Nagle Nunc International, 
Rochester, NY, USA). After washing with PBS, cells were fixed in 3% 
formaldehyde/PBS for 20 minutes at room temperature and permeabilized with 0.5% 
Triton X- 100/PBS for 5 minutes. Subsequently, cells were blocked for 30 minutes 
with 0.2% fish gelatine/PBS and incubated with the primary antibody diluted in 0.2% 
fish-gelatine/PBS for 60 minutes at room temperature. Dilutions of primary antibodies 
were as follows: mouse anti-BAMBI, 1:100; mouse anti-Smad2/3, 1:100; mouse anti-
p-Smad2 (Millipore Corporation, Billerica, MA, USA), 1:100; rabbit anti-calnexin 
(personal gift of Dr. Ivessa), 1:200; and rhodamine-phalloidin (Invitrogen, Carlsbad, 
CA, USA), 1:75. Cye-dye-conjugated secondary antibodies (The Jackson 
Laboratories, Bar Harbor, ME, USA) were applied for 45 minutes at room 
temperature at a dilution of 1:100 in 0.2% fish gelatine/PBS. Nuclei were stained by 
incubation with DAPI (Sigma-Aldrich, St. Louis, MO, USA) or ToPro3 (Invitrogen) 
together with the secondary antibody dilutions. Conventional microscopy was 
performed on an Olympus BX50 upright light microscope (Olympus Europe, 
Hamburg, Germany) equipped with the Soft Imaging system F-View for fluorescence 
image acquisition.  
6.5.6 Subcellular Fractionation and Western Blotting Analysis 
Cells grown in T75 flasks were rinsed with 5 ml PBS, harvested in RPMI medium with 
a rubber policeman and collected at 270 gmax for 10 minutes. The cells were 
resuspended in medium and treated with 20 ng ml-1 TGF- for 9 minutes at room 
temperature. Then the cells were immediately harvested at 4300 gmax and 4°C for 4 
minutes, resuspended in 3 ml buffer A (250 mM sucrose, 10 mM triethanolamine, pH 
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7.4, 1 mM EGTA) complemented with Complete protease inhibitors (F. Hoffmann-La 
Roche Ltd, Basel, Switzerland) and phosphatase inhibitor cocktail II (Sigma-Aldrich, 
St. Louis, MO, USA) and lysed with a tightly fitting Potter teflon pestle for 4 minutes. 
Nuclei and unbroken cells were pelleted at 1000 gmax for 10 minutes and 
resuspended in 4 ml 2.2 M sucrose, 1 mM MgCl2, 10 mM Tris, pH 7.4 with a loose 
Potter pestle. Pure nuclei were repelleted at 70,000 gmax for 80 min in a Beckman L8-
M ultracentrifuge (SW 50.1 rotor) and washed with 4 ml buffer A at 1000 gmax. The 
mitochondria and lysosomes were pelleted from the post-nuclear supernatant at 
20,200 gmax for 15 minutes. The microsomes were pelleted from the last supernatant 
at 182,000 gmax for 40 minutes and washed with 4 ml buffer A. The post-microsomal 
supernatant was kept as the cytosolic fraction. The final pellets were resuspended in 
buffer A and stored at -20°C. All centrifugation and resuspension steps were 
performed at 4°C. For Western analysis, 5 µg protein of each subcellular fraction 
(except 15 µg for the cytoplasmic fraction) was loaded. The antibodies used were: 
anti-BAMBI, anti-Smad2/3, anti-nucleoporin p62 (1:1000, BD Biosciences, San Jose, 
CA, USA), rabbit anti-actin HRP-conjugate, polyclonal goat anti-mouse HRP-
conjugate (specifications as described above). 
6.5.7 Statistical Analysis 
Continuous variables are presented as mean with standard deviation, categorical 
variables as absolute and relative frequencies. The significance of differences in 
doubling time, migration and invasion was calculated using t-test analysis. 
Correlation of TGF-ß concentration and BAMBI expression was calculated with 
Pearson correlation. In order to compare frequencies between two or more groups, 
Pearson's Chi-Square test was performed. In case of a sufficient approximation to a 
normal distribution, means and 95% confidence intervals for BAMBI expression were 
calculated on a logarithmic scale and then transformed back to the original scale. In 
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order to compare BAMBI expression between two or more groups, a t-test or one-
way ANOVA, respectively, was performed using the log-transformed expression as 
independent variable. The potential influence of BAMBI expression and of FIGO 
stage on overall survival is presented in plots of the corresponding Kaplan-Meier 
estimates and quantified using the Cox proportional hazards regression model. P-
values ≤ 0.05 were considered to be statistically significant. All computations have 
been performed using SPSS software version 15.0 (SPSS Inc. Headquarters, 
Chicago, Illinois, USA). 
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